<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN"  "JATS-archivearticle1-3-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic" pub-type="epub">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">92243</article-id><article-id pub-id-type="doi">10.7554/eLife.92243</article-id><article-id pub-id-type="doi" specific-use="version">10.7554/eLife.92243.3</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Advance</subject></subj-group><subj-group subj-group-type="heading"><subject>Medicine</subject></subj-group></article-categories><title-group><article-title>Membrane-bound <italic>O</italic>-acyltransferase 7 (MBOAT7) shapes lysosomal lipid homeostasis and function to control alcohol-associated liver injury</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-149266"><name><surname>Varadharajan</surname><given-names>Venkateshwari</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-4557-9840</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-159768"><name><surname>Ramachandiran</surname><given-names>Iyappan</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="other" rid="fund15"/><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-149271"><name><surname>Massey</surname><given-names>William J</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-2087-6048</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-323066"><name><surname>Jain</surname><given-names>Raghav</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-1284-6762</contrib-id><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="other" rid="fund12"/><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-149267"><name><surname>Banerjee</surname><given-names>Rakhee</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-261749"><name><surname>Horak</surname><given-names>Anthony J</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-265549"><name><surname>McMullen</surname><given-names>Megan R</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-265532"><name><surname>Huang</surname><given-names>Emily</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-265522"><name><surname>Bellar</surname><given-names>Annette</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-333463"><name><surname>Lorkowski</surname><given-names>Shuhui W</given-names></name><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-333464"><name><surname>Gulshan</surname><given-names>Kailash</given-names></name><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="fn" rid="con11"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-212453"><name><surname>Helsley</surname><given-names>Robert N</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-5000-3187</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff8">8</xref><xref ref-type="other" rid="fund13"/><xref ref-type="other" rid="fund14"/><xref ref-type="fn" rid="con12"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-333465"><name><surname>James</surname><given-names>Isabella</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0009-0000-2796-3497</contrib-id><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con13"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-265551"><name><surname>Pathak</surname><given-names>Vai</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="con14"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-333466"><name><surname>Dasarathy</surname><given-names>Jaividhya</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff9">9</xref><xref ref-type="fn" rid="con15"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-333467"><name><surname>Welch</surname><given-names>Nicole</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="con16"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-39729"><name><surname>Dasarathy</surname><given-names>Srinivasan</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-1774-0104</contrib-id><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="other" rid="fund1"/><xref ref-type="fn" rid="con17"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-333468"><name><surname>Streem</surname><given-names>David</given-names></name><xref ref-type="aff" rid="aff10">10</xref><xref ref-type="fn" rid="con18"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-325207"><name><surname>Reizes</surname><given-names>Ofer</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con19"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-109976"><name><surname>Allende</surname><given-names>Daniela S</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff11">11</xref><xref ref-type="other" rid="fund1"/><xref ref-type="fn" rid="con20"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-52322"><name><surname>Smith</surname><given-names>Jonathan D</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-0415-386X</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund8"/><xref ref-type="fn" rid="con21"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-162280"><name><surname>Simcox</surname><given-names>Judith</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-7350-6342</contrib-id><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="other" rid="fund9"/><xref ref-type="other" rid="fund10"/><xref ref-type="other" rid="fund11"/><xref ref-type="other" rid="fund12"/><xref ref-type="fn" rid="con22"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-333469"><name><surname>Nagy</surname><given-names>Laura E</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund5"/><xref ref-type="fn" rid="con23"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-51657"><name><surname>Brown</surname><given-names>J Mark</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-2708-7487</contrib-id><email>brownm5@ccf.org</email><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund2"/><xref ref-type="other" rid="fund3"/><xref ref-type="other" rid="fund4"/><xref ref-type="other" rid="fund5"/><xref ref-type="other" rid="fund6"/><xref ref-type="other" rid="fund7"/><xref ref-type="fn" rid="con24"/><xref ref-type="fn" rid="conf2"/></contrib><aff id="aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03xjacd83</institution-id><institution>Department of Cancer Biology, Lerner Research Institute of the Cleveland Clinic</institution></institution-wrap><addr-line><named-content content-type="city">Cleveland</named-content></addr-line><country>United States</country></aff><aff id="aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03xjacd83</institution-id><institution>Center for Microbiome and Human Health, Lerner Research Institute, Cleveland Clinic</institution></institution-wrap><addr-line><named-content content-type="city">Cleveland</named-content></addr-line><country>United States</country></aff><aff id="aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03xjacd83</institution-id><institution>Northern Ohio Alcohol Center (NOAC), Lerner Research Institute, Cleveland Clinic</institution></institution-wrap><addr-line><named-content content-type="city">Cleveland</named-content></addr-line><country>United States</country></aff><aff id="aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01y2jtd41</institution-id><institution>Department of Biochemistry, University of Wisconsin-Madison</institution></institution-wrap><addr-line><named-content content-type="city">Madison</named-content></addr-line><country>United States</country></aff><aff id="aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03xjacd83</institution-id><institution>Department of Inflammation and Immunity, Lerner Research Institute, Cleveland Clinic</institution></institution-wrap><addr-line><named-content content-type="city">Cleveland</named-content></addr-line><country>United States</country></aff><aff id="aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03xjacd83</institution-id><institution>Department of Cardiovascular and Metabolic Sciences, Lerner Research Institute of the Cleveland Clinic</institution></institution-wrap><addr-line><named-content content-type="city">Cleveland</named-content></addr-line><country>United States</country></aff><aff id="aff7"><label>7</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/002tx1f22</institution-id><institution>Center for Gene Regulation in Health and Disease (GRHD), Cleveland State University</institution></institution-wrap><addr-line><named-content content-type="city">Cleveland</named-content></addr-line><country>United States</country></aff><aff id="aff8"><label>8</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02k3smh20</institution-id><institution>Department of Pharmacology &amp; Nutritional Sciences, Saha Cardiovascular Research Center, University of Kentucky College of Medicine</institution></institution-wrap><addr-line><named-content content-type="city">Lexington</named-content></addr-line><country>United States</country></aff><aff id="aff9"><label>9</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/051fd9666</institution-id><institution>Department of Family Medicine, Metro Health Medical Center, Case Western Reserve University</institution></institution-wrap><addr-line><named-content content-type="city">Cleveland</named-content></addr-line><country>United States</country></aff><aff id="aff10"><label>10</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03xjacd83</institution-id><institution>Lutheran Hospital, Cleveland Clinic</institution></institution-wrap><addr-line><named-content content-type="city">Cleveland</named-content></addr-line><country>United States</country></aff><aff id="aff11"><label>11</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03xjacd83</institution-id><institution>Department of Anatomical Pathology, Cleveland Clinic</institution></institution-wrap><addr-line><named-content content-type="city">Cleveland</named-content></addr-line><country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Mistry</surname><given-names>Pramod K</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03v76x132</institution-id><institution>Yale University</institution></institution-wrap><country>United States</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Mistry</surname><given-names>Pramod K</given-names></name><role>Senior Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03v76x132</institution-id><institution>Yale University</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group><pub-date publication-format="electronic" date-type="publication"><day>22</day><month>04</month><year>2024</year></pub-date><volume>12</volume><elocation-id>RP92243</elocation-id><history><date date-type="sent-for-review" iso-8601-date="2023-09-11"><day>11</day><month>09</month><year>2023</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint.</event-desc><date date-type="preprint" iso-8601-date="2023-09-27"><day>27</day><month>09</month><year>2023</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2023.09.26.559533"/></event><event><event-desc>This manuscript was published as a reviewed preprint.</event-desc><date date-type="reviewed-preprint" iso-8601-date="2023-12-27"><day>27</day><month>12</month><year>2023</year></date><self-uri content-type="reviewed-preprint" xlink:href="https://doi.org/10.7554/eLife.92243.1"/></event><event><event-desc>The reviewed preprint was revised.</event-desc><date date-type="reviewed-preprint" iso-8601-date="2024-03-04"><day>04</day><month>03</month><year>2024</year></date><self-uri content-type="reviewed-preprint" xlink:href="https://doi.org/10.7554/eLife.92243.2"/></event></pub-history><permissions><copyright-statement>© 2023, Varadharajan et al</copyright-statement><copyright-year>2023</copyright-year><copyright-holder>Varadharajan et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-92243-v1.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-92243-figures-v1.pdf"/><related-article related-article-type="article-reference" ext-link-type="doi" xlink:href="10.7554/eLife.49882" id="ra1"/><abstract><p>Recent genome-wide association studies (GWAS) have identified a link between single-nucleotide polymorphisms (SNPs) near the MBOAT7 gene and advanced liver diseases. Specifically, the common MBOAT7 variant (rs641738) associated with reduced MBOAT7 expression is implicated in non-alcoholic fatty liver disease (NAFLD), alcohol-associated liver disease (ALD), and liver fibrosis. However, the precise mechanism underlying MBOAT7-driven liver disease progression remains elusive. Previously, we identified MBOAT7-driven acylation of lysophosphatidylinositol lipids as key mechanism suppressing the progression of NAFLD (Gwag et al., 2019). Here, we show that MBOAT7 loss of function promotes ALD via reorganization of lysosomal lipid homeostasis. Circulating levels of MBOAT7 metabolic products are significantly reduced in heavy drinkers compared to healthy controls. Hepatocyte- (<italic>Mboat7</italic>-HSKO), but not myeloid-specific (<italic>Mboat7</italic>-MSKO), deletion of <italic>Mboat7</italic> exacerbates ethanol-induced liver injury. Lipidomic profiling reveals a reorganization of the hepatic lipidome in <italic>Mboat7</italic>-HSKO mice, characterized by increased endosomal/lysosomal lipids. Ethanol-exposed <italic>Mboat7</italic>-HSKO mice exhibit dysregulated autophagic flux and lysosomal biogenesis, associated with impaired transcription factor EB-mediated lysosomal biogenesis and autophagosome accumulation. This study provides mechanistic insights into how MBOAT7 influences ALD progression through dysregulation of lysosomal biogenesis and autophagic flux, highlighting hepatocyte-specific MBOAT7 loss as a key driver of ethanol-induced liver injury.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>MBOAT7</kwd><kwd>alcohol-associated liver disease</kwd><kwd>autophagy</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Mouse</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000052</institution-id><institution>NIH Office of the Director</institution></institution-wrap></funding-source><award-id>P50 AA024333</award-id><principal-award-recipient><name><surname>Dasarathy</surname><given-names>Srinivasan</given-names></name><name><surname>Allende</surname><given-names>Daniela S</given-names></name><name><surname>Smith</surname><given-names>Jonathan D</given-names></name><name><surname>Nagy</surname><given-names>Laura E</given-names></name><name><surname>Brown</surname><given-names>J Mark</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000052</institution-id><institution>NIH Office of the Director</institution></institution-wrap></funding-source><award-id>R01 DK120679</award-id><principal-award-recipient><name><surname>Brown</surname><given-names>J Mark</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000052</institution-id><institution>NIH Office of the Director</institution></institution-wrap></funding-source><award-id>RF1 NS133812</award-id><principal-award-recipient><name><surname>Brown</surname><given-names>J Mark</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000052</institution-id><institution>NIH Office of the Director</institution></institution-wrap></funding-source><award-id>P01 HL147823</award-id><principal-award-recipient><name><surname>Brown</surname><given-names>J Mark</given-names></name></principal-award-recipient></award-group><award-group id="fund5"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000052</institution-id><institution>NIH Office of the Director</institution></institution-wrap></funding-source><award-id>U01 AA026938</award-id><principal-award-recipient><name><surname>Nagy</surname><given-names>Laura E</given-names></name><name><surname>Brown</surname><given-names>J Mark</given-names></name></principal-award-recipient></award-group><award-group id="fund6"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000052</institution-id><institution>NIH Office of the Director</institution></institution-wrap></funding-source><award-id>R01 DK130227</award-id><principal-award-recipient><name><surname>Brown</surname><given-names>J Mark</given-names></name></principal-award-recipient></award-group><award-group id="fund7"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000052</institution-id><institution>NIH Office of the Director</institution></institution-wrap></funding-source><award-id>U01 AA026264</award-id><principal-award-recipient><name><surname>Brown</surname><given-names>J Mark</given-names></name></principal-award-recipient></award-group><award-group id="fund8"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000052</institution-id><institution>NIH Office of the Director</institution></institution-wrap></funding-source><award-id>R01 HL128268</award-id><principal-award-recipient><name><surname>Smith</surname><given-names>Jonathan D</given-names></name></principal-award-recipient></award-group><award-group id="fund9"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100022690</institution-id><institution>JDRF</institution></institution-wrap></funding-source><award-id>JDRF201309442</award-id><principal-award-recipient><name><surname>Simcox</surname><given-names>Judith</given-names></name></principal-award-recipient></award-group><award-group id="fund10"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100001642</institution-id><institution>Glenn Foundation for Medical Research</institution></institution-wrap></funding-source><award-id>A22068</award-id><principal-award-recipient><name><surname>Simcox</surname><given-names>Judith</given-names></name></principal-award-recipient></award-group><award-group id="fund11"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000052</institution-id><institution>NIH Office of the Director</institution></institution-wrap></funding-source><award-id>R01 DK133479</award-id><principal-award-recipient><name><surname>Simcox</surname><given-names>Judith</given-names></name></principal-award-recipient></award-group><award-group id="fund12"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100007015</institution-id><institution>University of Wisconsin-Madison</institution></institution-wrap></funding-source><award-id>WIS04000</award-id><principal-award-recipient><name><surname>Jain</surname><given-names>Raghav</given-names></name><name><surname>Simcox</surname><given-names>Judith</given-names></name></principal-award-recipient></award-group><award-group id="fund13"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000052</institution-id><institution>NIH Office of the Director</institution></institution-wrap></funding-source><award-id>DK128022</award-id><principal-award-recipient><name><surname>Helsley</surname><given-names>Robert N</given-names></name></principal-award-recipient></award-group><award-group id="fund14"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100007472</institution-id><institution>University of Kentucky</institution></institution-wrap></funding-source><award-id>UL1TR001998</award-id><principal-award-recipient><name><surname>Helsley</surname><given-names>Robert N</given-names></name></principal-award-recipient></award-group><award-group id="fund15"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000968</institution-id><institution>American Heart Association</institution></institution-wrap></funding-source><award-id>19POST34380725</award-id><principal-award-recipient><name><surname>Ramachandiran</surname><given-names>Iyappan</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection, and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>MBOAT7 loss of function in hepatocytes contributes to ethanol-induced liver injury, offering crucial insights into the dysregulated lipid metabolism and impaired autophagy associated with advanced liver disease.</meta-value></custom-meta><custom-meta specific-use="meta-only"><meta-name>publishing-route</meta-name><meta-value>prc</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>End-stage liver diseases account for approximately 2 million deaths annually worldwide, with nearly half of liver disease-associated deaths arising from complications of alcohol-associated and non-alcoholic fatty liver disease (NAFLD)-related cirrhosis, and the other half driven by viral hepatitis and hepatocellular carcinoma. It is generally appreciated that there are some shared mechanisms driving liver injury from viral, NAFLD, or alcohol-associated liver disease (ALD)-driven etiologies, but also etiology-specific drivers that uniquely shape the pathogenesis of liver failure. Although there has been great progress in identifying the ‘multiple hits’ that lead to end-stage liver disease, we are only beginning to understand the cellular and molecular mechanisms driving etiology-specific liver disease progression. Within the evolving ‘multiple hit’ theory of liver disease progression, it is clear that interactions between environmental factors (i.e., diet, microbiome, alcohol, viral infection, environmental toxins, etc.) and genetic determinants uniquely contribute to liver injury (<xref ref-type="bibr" rid="bib14">Cohen et al., 2011</xref>; <xref ref-type="bibr" rid="bib33">Rinella and Sanyal, 2016</xref>). Currently, the only option for end-stage liver disease is liver transplantation. However, the availability of viable donor livers is finite, and pharmacological approaches to improve outcomes are simply lacking due to our poor understanding of the underlying mechanisms of disease pathogenesis. Given this, there is a clear need to understand the genetic and environmental interactions promoting the progression of liver disease from simple steatosis to more advanced inflammatory and fibrotic disease. We address this gap here by investigating the mechanisms linking a recently identified liver disease susceptibility gene in combination with alcohol exposure.</p><p>Genome-wide association studies (GWAS) provide a powerful unbiased tool to identify new genes contributing to human disease, allowing for pinpoint accuracy in identification of new potential drug targets. This is exemplified by the recent success story of GWAS discoveries leading to rapid development of monoclonal antibodies targeting proprotein convertase subtilisin/kexin type 9 (PCSK9) for hyperlipidemia and cardiovascular diseases (<xref ref-type="bibr" rid="bib36">Sabatine, 2019</xref>). Since 2015, several independent GWAS studies have identified a liver disease susceptibility locus (rs641738) near the genes encoding <italic>MBOAT7</italic> and <italic>TMC4</italic> (<xref ref-type="bibr" rid="bib10">Buch et al., 2015</xref>; <xref ref-type="bibr" rid="bib27">Mancina et al., 2016</xref>; <xref ref-type="bibr" rid="bib25">Krawczyk et al., 2017</xref>; <xref ref-type="bibr" rid="bib44">Thabet et al., 2016</xref>; <xref ref-type="bibr" rid="bib45">Thabet et al., 2017</xref>; <xref ref-type="bibr" rid="bib43">Teo et al., 2021</xref>). It is important to note that the rs641738 T-allele (~43% allele frequency in European ancestry populations) is associated with all major forms of liver injury including NAFLD, ALD, and viral hepatitis-induced fibrosis (<xref ref-type="bibr" rid="bib10">Buch et al., 2015</xref>; <xref ref-type="bibr" rid="bib27">Mancina et al., 2016</xref>; <xref ref-type="bibr" rid="bib25">Krawczyk et al., 2017</xref>; <xref ref-type="bibr" rid="bib44">Thabet et al., 2016</xref>; <xref ref-type="bibr" rid="bib45">Thabet et al., 2017</xref>; <xref ref-type="bibr" rid="bib43">Teo et al., 2021</xref>). The rs641738 variant is associated with a C&gt;T missense single-nucleotide polymorphism (SNP) within the first exon the <italic>TMC4</italic> gene, but the GTEx project shows that <italic>TMC4</italic> is not abundantly expressed in human liver (1.4 transcripts per million). We previously showed that mice lacking <italic>Tmc4</italic> (<italic>Tmc4</italic><sup>−/−</sup>) have normal high fat diet-induced hepatic steatosis (<xref ref-type="bibr" rid="bib21">Gwag et al., 2019</xref>). We also recently demonstrated that antisense oligonucleotide (ASO)-mediated knockdown of <italic>Mboat7</italic> promotes insulin resistance, hepatic steatosis, hepatocyte death, inflammation, and early fibrosis in high fat diet-fed mice (<xref ref-type="bibr" rid="bib21">Gwag et al., 2019</xref>). In parallel, four independent groups also showed that <italic>Mboat7</italic> loss of function promotes hepatic steatosis, inflammation, and fibrosis in mice (<xref ref-type="bibr" rid="bib29">Meroni et al., 2020</xref>; <xref ref-type="bibr" rid="bib42">Tanaka et al., 2021</xref>; <xref ref-type="bibr" rid="bib46">Thangapandi et al., 2021</xref>; <xref ref-type="bibr" rid="bib49">Xia et al., 2021</xref>). Collectively, <italic>MBOAT7</italic> is a genetic determinant of advanced liver disease, but how this gene shapes susceptibility to environmental cues is still an area of intense investigation.</p><p>The <italic>MBOAT7</italic> gene encodes a lysophospholipid acyltransferase enzyme (also known as lysophosphatidylinositol acyltransferase 1, LPIAT1), which uniquely contributes to the Land’s cycle of membrane phospholipid remodeling (<xref ref-type="bibr" rid="bib39">Shindou and Shimizu, 2009</xref>). The Land’s cycle is a series of phospholipase-driven deacylation and lysophospholipid acyltransferase-driven acylation reactions that shape membrane asymmetry and diversity (<xref ref-type="bibr" rid="bib39">Shindou and Shimizu, 2009</xref>). It is important to note that MBOAT7 selectively diversifies the fatty acid composition of membrane phosphatidylinositol (PI) species and not phospholipids with other head groups and exhibits acyl chain specificity for polyunsaturated fatty acids (<xref ref-type="bibr" rid="bib39">Shindou and Shimizu, 2009</xref>; <xref ref-type="bibr" rid="bib17">Gijón et al., 2008</xref>; <xref ref-type="bibr" rid="bib50">Zarini et al., 2014</xref>). This substrate specificity has been observed in in vitro or cell-based studies (<xref ref-type="bibr" rid="bib17">Gijón et al., 2008</xref>; <xref ref-type="bibr" rid="bib50">Zarini et al., 2014</xref>), which has been confirmed in vivo in mice with diminished <italic>Mboat7</italic> function (<xref ref-type="bibr" rid="bib21">Gwag et al., 2019</xref>; <xref ref-type="bibr" rid="bib29">Meroni et al., 2020</xref>; <xref ref-type="bibr" rid="bib42">Tanaka et al., 2021</xref>; <xref ref-type="bibr" rid="bib46">Thangapandi et al., 2021</xref>; <xref ref-type="bibr" rid="bib49">Xia et al., 2021</xref>). Although MBOAT7 is well documented to directly modulate PI lipids, the Land’s cycle is highly dynamic and has the potential to influence many downstream metabolic processes as well as cell signaling. Here, we report that ethanol-induced perturbation of the hepatic lipidome is powerfully shaped by MBOAT7 function in hepatocytes. This MBOAT7-dependent reorganization of the hepatic lipidome in response to ethanol is also functionally tied to diminished lysosome function and defective autophagy. This work shows that MBOAT7 uniquely contributes to ethanol-induced liver injury via perturbations of hepatic lipid metabolism that extend beyond the direct remodeling of membrane PI.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>Heavy drinkers have reduced circulating levels of MBOAT7 enzymatic products</title><p>Given previous studies have shown that MBOAT7 is a risk locus for alcohol-associated cirrhosis (<xref ref-type="bibr" rid="bib10">Buch et al., 2015</xref>), we investigated whether active alcohol consumption was associated with alterations in MBOAT7 function. To address this, we measured both lysophosphatidylinositol (LPI) substrates and PI products of the MBOAT7 enzymatic reaction in the circulation of healthy controls compared to confirmed heavy drinkers (<xref ref-type="fig" rid="fig1">Figure 1</xref>). Heavy drinkers were recruited and defined by an AUDIT score (<xref ref-type="bibr" rid="bib15">Fleming et al., 1991</xref>) greater than 16, and compared to an age- and sex-matched healthy control population (<xref ref-type="supplementary-material" rid="fig1sdata1">Figure 1—source data 1</xref>). In agreement with genetic studies linking MBOAT7 variants to alcohol-associated cirrhosis (<xref ref-type="bibr" rid="bib10">Buch et al., 2015</xref>), we find that circulating levels of metabolic products of MBOAT7 including arachidonic acid- and eicosapentaenoic acid-containing phophosphatidylinositols (PI 38:4 and PI 38:5) are significantly reduced in heavy drinkers compared to age-matched healthy controls (<xref ref-type="fig" rid="fig1">Figure 1</xref>). Given MBOAT7 demonstrates specificity for polyunsaturated (PUFA) acyl-CoA substrates (<xref ref-type="bibr" rid="bib17">Gijón et al., 2008</xref>), it is important to note that only select PUFA-containing MBOAT7 products (PI 38:4 and PI 38:5) were reduced in heavy drinkers, whereas all other molecular species of PI were unaltered. We also examined the circulating levels LPI substrates of MBOAT7 but found no significant differences between controls and heavy drinkers (<xref ref-type="fig" rid="fig1">Figure 1</xref>). These data show that excessive alcoholic intake is associated with reduced levels of MBOAT7 product lipids, which further bolsters the concept that MBOAT7 loss of function may be causally linked to ALD progression.</p><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>MBOAT7 products are selectively reduced in heavy drinkers.</title><p>Plasma lysophosphatidylinositol (LPI – inset graph) and phosphatidylinositol (PI) species from both male and female healthy controls and heavy drinkers were measured by liquid chromatography–tandem mass spectrometry (LC–MS/MS). <italic>n</italic> = 10–16; ***p &lt; 0.001 and ****p &lt; 0.0001 in the figure. Analysis of variance (ANOVA) with Tukey’s post hoc test.</p><p><supplementary-material id="fig1sdata1"><label>Figure 1—source data 1.</label><caption><title>Demographic and clinical parameters for the entire cohort of healthy controls and heavy drinkers recruited for this study.</title></caption><media mimetype="application" mime-subtype="docx" xlink:href="elife-92243-fig1-data1-v1.docx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-92243-fig1-v1.tif"/></fig></sec><sec id="s2-2"><title>MBOAT7 loss of function in hepatocytes, but not myeloid cells, facilitates ethanol-induced liver injury in mice</title><p>Although there is some emerging evidence that MBOAT7 genetic variants may predispose humans to alcohol-induced liver injury (<xref ref-type="bibr" rid="bib10">Buch et al., 2015</xref>), not all human studies have found a significant association (<xref ref-type="bibr" rid="bib51">Zhang et al., 2018</xref>; <xref ref-type="bibr" rid="bib41">Stickel et al., 2018</xref>; <xref ref-type="bibr" rid="bib5">Beaudoin et al., 2021</xref>). Importantly, a causal relationship between MBOAT7 and alcohol-induced liver injury has never been established to date. To address this, we have studied ethanol-induced liver injury in mice selectively lacking <italic>Mboat7</italic> in hepatocytes or myeloid cells, given the key roles that hepatocytes and myeloid cells play in the pathogenesis of ethanol-induced liver disease progression. To generate congenic hepatocyte-specific (<italic>Mboat7</italic>-HSKO) and myeloid-specific (<italic>Mboat7</italic>-MSKO) <italic>Mboat7</italic> knockout mice we crossed mice harboring a post-FLP recombinase conditionally targeted <italic>Mboat7</italic> floxed allele (<xref ref-type="bibr" rid="bib2">Anderson et al., 2013</xref>; <xref ref-type="bibr" rid="bib28">Massey et al., 2023</xref>) to mice transgenically expressing Cre recombinase under the albumin promoter/enhancer (<xref ref-type="bibr" rid="bib32">Postic et al., 1999</xref>) or Cre knocked into the M lysozyme locus (<xref ref-type="bibr" rid="bib13">Clausen et al., 1999</xref>), respectively. These independent <italic>Mboat7</italic>-HSKO and <italic>Mboat7</italic>-MSKO lines were then backcrossed mice &gt;10 generations into the C57BL/6J background and subsequently subjected to ethanol exposure. Compared to control mice (<italic>Mboat7</italic><sup>flox/flox</sup>), <italic>Mboat7</italic>-HSKO mice had significantly reduced <italic>Mboat7</italic> mRNA and protein expression in the liver (<xref ref-type="fig" rid="fig2">Figure 2A, B</xref>), but not in other tissues (data not shown; <xref ref-type="bibr" rid="bib28">Massey et al., 2023</xref>). Hepatocyte-specific deletion of <italic>Mboat7</italic> resulted in enhanced ethanol-induced increases in liver weight and high concentrations of plasma alanine aminotransferase (ALT) (<xref ref-type="fig" rid="fig2">Figure 2C, D</xref>). Likewise, <italic>Mboat7</italic>-HSKO mice showed elevated hepatic steatosis scores and triglyceride levels under both pair-fed and ethanol-fed conditions (<xref ref-type="fig" rid="fig2">Figure 2E, F</xref>). However, hepatocyte-specific deletion of <italic>Mboat7</italic> did not significantly alter the mRNA expression for several proinflammatory cytokines/chemokines including tumor necrosis factor α (<italic>Tnfa</italic>), transforming growth factor β (<italic>Tgfb</italic>), monocyte chemoattractant protein 1 (<italic>Mcp1</italic>), or interleukins 1β (<italic>Il1b</italic>) or 6 (<italic>Il6</italic>) in either pair- or ethanol-fed conditions (<xref ref-type="fig" rid="fig2">Figure 2G</xref>). These data demonstrate that MBOAT7 function in hepatocytes is a critical determinant of ethanol-induced liver injury, but we also wanted to explore a potential role for MBOAT7 in non-parenchymal cells given the key roles that macrophages and neutrophils play in ALD.</p><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>Hepatocyte-specific deletion of <italic>Mboat7</italic> promotes ethanol-induced liver injury.</title><p>Female control (<italic>Mboat7<sup>fl/fl</sup></italic>) or hepatocyte-specific <italic>Mboat7</italic> knockout mice (<italic>Mboat7</italic>-HSKO) were fed with subjected the NIAAA (National Institute on Alcohol Abuse and Alcoholism) model of ethanol-induced liver injury. (<bold>A</bold>) Hepatic <italic>Mboat7</italic> expression was measured via quantitative polymerase chain reaction (qPCR). (<bold>B</bold>) Western blot for hepatic microsomal MBOAT7 protein levels replicated in <italic>n</italic> = 3 mice. (<bold>C</bold>) Liver weight, (<bold>D</bold>) plasma alanine aminotransferase (ALT), (<bold>E</bold>) percent steatosis quantified by a blinded board-certified pathologist, (<bold>F</bold>) hepatic triglycerides, and (<bold>G</bold>) hepatic expression of inflammatory gene measured by qPCR. <italic>n</italic> = 5–7. Data represent the mean ± standard error of the mean (SEM) and groups not sharing a common letter superscript differ significantly (p ≤ 0.05).</p><p><supplementary-material id="fig2sdata1"><label>Figure 2—source data 1.</label><caption><title>Original file for the western blot analysis in <xref ref-type="fig" rid="fig2">Figure 2B</xref> (anti-MBOAT7 and anti-β-actin).</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-92243-fig2-data1-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig2sdata2"><label>Figure 2—source data 2.</label><caption><title>PDF containing <xref ref-type="fig" rid="fig2">Figure 2B</xref> and original scans of the relevant western blot analysis (anti-MBOAT7 and anti-β-actin) with highlighted bands and sample labels.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-92243-fig2-data2-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-92243-fig2-v1.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 1.</label><caption><title>Myeloid-specific deletion of <italic>Mboat7</italic> does not promote ethanol-induced liver injury.</title><p>Female control (Mboat7<italic><sup>fl/fl</sup></italic>) or myeloid-specific <italic>Mboat7</italic> knockout mice (<italic>Mboat7</italic>-MSKO) were subjected to the NIAAA model of ethanol-induced liver injury. (<bold>A</bold>) Western blots from bone marrow derived macrophage (BMDM) or peritoneal macrophage (PM) collected from <italic>Mboat7<sup>fl/fl</sup></italic> or <italic>Mboat7</italic>-MSKO mice. (<bold>B</bold>) Initial and final body weight measured in <italic>Mboat7</italic><sup>fl/fl</sup> or <italic>Mboat7</italic>-MSKO mice. (<bold>C</bold>) Liver weight, (<bold>D, E</bold>) plasma alanine aminotransferase (ALT) and aspartate aminotransferase (AST), (<bold>F</bold>) hepatic triglycerides, and (<bold>G</bold>) hepatic expression of inflammatory gene measured by qPCR. Data represent the mean ± standard error of the mean (SEM) and groups not sharing a common letter superscript differ significantly (p ≤ 0.05).</p><p><supplementary-material id="fig2s1sdata1"><label>Figure 2—figure supplement 1—source data 1.</label><caption><title>Original file for the western blot analysis in <xref ref-type="fig" rid="fig2">Figure 2A</xref> (anti-MBOAT7 and anti-β-actin).</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-92243-fig2-figsupp1-data1-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig2s1sdata2"><label>Figure 2—figure supplement 1—source data 2.</label><caption><title>PDF containing <xref ref-type="fig" rid="fig2">Figure 2A</xref> and original scans of the relevant western blot analysis (anti-MBOAT7 and anti-β-actin) with highlighted bands and sample labels.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-92243-fig2-figsupp1-data2-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-92243-fig2-figsupp1-v1.tif"/></fig></fig-group><p>It is important to note during the preparation of this manuscript, an independent study discovered a potential role for MBOAT7 in suppressing toll-like receptor signaling and proinflammatory cytokine production in macrophages and Kupffer cells in the context of NAFLD (<xref ref-type="bibr" rid="bib1">Alharthi et al., 2022</xref>). Furthermore, early studies examining the expression and substrate specificity for diverse lysophospholipid acyltransferases showed that MBOAT7-driven PI remodeling was highly active in human neutrophils where it can modulate the production of proinflammatory arachidonic acid-derived lipid mediators (<xref ref-type="bibr" rid="bib17">Gijón et al., 2008</xref>). Therefore, we generated myeloid-specific (<italic>Mboat7</italic>-MSKO) <italic>Mboat7</italic> knockout mice to further interrogate cell autonomous roles in ALD progression. First to confirm efficient deletion in myeloid cells, we isolated both bone marrow-derived and thioglycolate-elicited macrophages from control and myeloid-specific (<italic>Mboat7</italic>-MSKO) <italic>Mboat7</italic> knockout mice, which confirmed essentially no detectable MBOAT7 protein in <italic>Mboat7</italic>-MSKO mice (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref>). In contrast to the enhanced ethanol-induced liver injury seen in <italic>Mboat7</italic>-HSKO mice (<xref ref-type="fig" rid="fig2">Figure 2</xref>), myeloid-specific (<italic>Mboat7</italic>-MSKO) <italic>Mboat7</italic> deletion resulted in unaltered ethanol-induced effects on body weight, liver weight, circulating levels of aspartate and alanine aminotransferases (AST and ALT), liver triglyceride, and cytokine expression (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref>). Collectively, these results demonstrate that MBOAT7 loss of function in hepatocytes, but not myeloid cells, facilitates ethanol-induced liver injury in mice.</p></sec><sec id="s2-3"><title>Ethanol exposure reorganizes the hepatic lipidome in a MBOAT7-dependent manner</title><p>Given the fact that ethanol exposure is well known to reorganize hepatic lipid metabolism, we performed comprehensive lipidomic profiling of the liver to understand how MBOAT7 could potentially shape ethanol-induced lipid metabolism in the liver. First, we used a targeted approach to measure the levels of MBOAT7 substrate LPIs and product PIs. Compared to control mice (<italic>Mboat7</italic><sup>flox/flox</sup>), <italic>Mboat7</italic>-HSKO mice had significant accumulation of palmitate- and oleate-containing LPI substrate lipids (LPI 16:0 and LPI 18:1), with large accumulation of LPI 16:0 under ethanol-fed conditions (<xref ref-type="fig" rid="fig3">Figure 3A</xref>). When we examined PI species, we confirmed previous findings that <italic>Mboat7</italic>-HSKO mice have reduced levels of the major arachidonic acid-containing PI (PI 38:4) and also striking reductions in PI 38:3 under both pair- and ethanol-fed conditions (<xref ref-type="fig" rid="fig3">Figure 3B</xref>). In addition, <italic>Mboat7</italic>-HSKO mice also have accumulation of several other PI species including PI 34:1, PI 36:1, PI 36:2, PI 38:6, and PI 40:6, some of which are exacerbated in the ethanol-fed group (<xref ref-type="fig" rid="fig3">Figure 3C</xref>). Although many of these changes in MBOAT7’s substrate LPIs and product PIs are expected based on MBOAT7’s substrate specificity and previous literature, there is a clear interaction between ethanol and MBOAT7 uncovered here that has not been observed in studies using NAFLD-related models (<xref ref-type="bibr" rid="bib42">Tanaka et al., 2021</xref>; <xref ref-type="bibr" rid="bib46">Thangapandi et al., 2021</xref>; <xref ref-type="bibr" rid="bib49">Xia et al., 2021</xref>).</p><fig-group><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>Ethanol alters the liver lipidome in a MBOAT7-dependent manner.</title><p><italic>Mboat</italic>7<sup>fl/fl</sup> or <italic>Mboat</italic>7-HSKO mice were subjected to the NIAAA model of ethanol exposure. Liver lysophosphatidylinositol (LPI) (<bold>A</bold>) and phosphatidylinositol (PI) species, including the MBOAT7 product PI 38:4 (<bold>B</bold>) and others (<bold>C</bold>), were quantified via liquid chromatography–tandem mass spectrometry (LC–MS/MS) in <italic>n</italic> = 5–7. (<bold>D</bold>) Principal component analysis for untargeted lipidomics analysis. The first and second principal components are plotted on the <italic>x</italic>- and <italic>y</italic>-axis, respectively, and sample treatment group is indicated by color. (<bold>E</bold>) Heatmap showing global lipidomic alterations in mouse liver. Total levels of endosomal/lysosomal lipids were measured by targeted and untargeted lipidomic approach using LC–MS/MS. (<bold>F</bold>) Total bis(monoacylglycero)phosphate (BMP) levels. (<bold>G</bold>) Total phosphatidylglycerol (PG) and (<bold>H</bold>) total cardiolipin (CL) from the liver of Mboat7<sup>fl/fl</sup> or Mboat7-HSKO mice. Data represent the mean ± standard error of the mean (SEM) and groups not sharing a common letter superscript differ significantly (p ≤ 0.05).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-92243-fig3-v1.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 1.</label><caption><title>Alterations in total hepatic lipid levels in <italic>Mboat7</italic>-HSKO mice.</title><p>Age-matched female <italic>Mboat</italic>7<sup>fl/fl</sup> or <italic>Mboat</italic>7-HSKO mice were subjected to the NIAAA model of ethanol exposure, and untargeted lipidomics was performed to broadly examine major lipid classes in the liver. (<bold>A</bold>) Phosphatidylcholine (PC), (<bold>B</bold>) phosphatidylserine (PS), (<bold>C</bold>) phosphatidylethanolamine (PE), (<bold>D</bold>) phosphatidic acid (PA), (<bold>E</bold>) sphingomyelins (SM), (<bold>F</bold>) ceramides (Cer), (<bold>G</bold>) ether phosphatidylcholine, (<bold>H</bold>) ether phosphatidylethanolamine, (<bold>I</bold>) free fatty acids (FFA), (<bold>J</bold>) hexosylceramide (HexCer), (<bold>K</bold>) diacylglycerol (DAG), and (<bold>L</bold>) cholesteryl ester (CE) were quantified via liquid chromatography–mass spectrometry (<italic>n</italic> = 6/group). Data represent the mean ± standard error of the mean (SEM) and groups not sharing a common letter superscript differ significantly (p ≤ 0.05).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-92243-fig3-figsupp1-v1.tif"/></fig><fig id="fig3s2" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 2.</label><caption><title>Hepatic phosphatidylcholine (PC) levels in <italic>Mboat7</italic>-HSKO mice.</title><p>Age-matched female <italic>Mboat</italic>7<sup>fl/fl</sup> or <italic>Mboat</italic>7-HSKO mice were subjected to the NIAAA model of ethanol exposure, and untargeted lipidomics were performed to broadly examine major lipid classes in the liver. The molecular species of PC were quantified via liquid chromatography–mass spectrometry (<italic>n</italic> = 6/group). Data represent the mean ± standard error of the mean (SEM) and groups not sharing a common letter superscript differ significantly (p ≤ 0.05).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-92243-fig3-figsupp2-v1.tif"/></fig><fig id="fig3s3" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 3.</label><caption><title>Hepatic bis(monoacylglycerol)phosphate (BMP) levels in <italic>Mboat7</italic>-HSKO mice.</title><p>Age-matched female <italic>Mboat</italic>7<sup>fl/fl</sup> or <italic>Mboat</italic>7-HSKO mice were subjected to the NIAAA model of ethanol exposure, and targeted lipidomics was performed in the liver. The molecular species of BMP were quantified via liquid chromatography–mass spectrometry (<italic>n</italic> = 6/group). Data represent the mean ± standard error of the mean (SEM) and groups not sharing a common letter superscript differ significantly (p ≤ 0.05).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-92243-fig3-figsupp3-v1.tif"/></fig><fig id="fig3s4" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 4.</label><caption><title>Hepatic phosphatidylglycerol (PG) levels in <italic>Mboat7</italic>-HSKO mice.</title><p>Age-matched female <italic>Mboat</italic>7<sup>fl/fl</sup> or <italic>Mboat</italic>7-HSKO mice were subjected to the NIAAA model of ethanol exposure, and targeted lipidomics was performed in the liver. The molecular species of PG were quantified via liquid chromatography–mass spectrometry (<italic>n</italic> = 6/group). Data represent the mean ± standard error of the mean (SEM) and groups not sharing a common letter superscript differ significantly (p ≤ 0.05).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-92243-fig3-figsupp4-v1.tif"/></fig><fig id="fig3s5" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 5.</label><caption><title>Hepatic cardiolipin (CL) levels in <italic>Mboat7</italic>-HSKO mice.</title><p>Age-matched female <italic>Mboat</italic>7<sup>fl/fl</sup> or <italic>Mboat</italic>7-HSKO mice were subjected to the NIAAA model of ethanol exposure, and untargeted lipidomics was performed in the liver. The molecular species of CL were quantified via liquid chromatography–mass spectrometry (<italic>n</italic> = 6/group). Data represent the mean ± standard error of the mean (SEM) and groups not sharing a common letter superscript differ significantly (p ≤ 0.05).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-92243-fig3-figsupp5-v1.tif"/></fig><fig id="fig3s6" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 6.</label><caption><title>Hepatic phosphatidylserine (PS) levels in <italic>Mboat7</italic>-HSKO mice.</title><p>Age-matched female <italic>Mboat</italic>7<sup>fl/fl</sup> or <italic>Mboat</italic>7-HSKO mice were subjected to the NIAAA model of ethanol exposure, and untargeted lipidomics was performed in the liver. The molecular species of PS were quantified via liquid chromatography–mass spectrometry (<italic>n</italic> = 6/group). Data represent the mean ± standard error of the mean (SEM) and groups not sharing a common letter superscript differ significantly (p ≤ 0.05).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-92243-fig3-figsupp6-v1.tif"/></fig><fig id="fig3s7" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 7.</label><caption><title>Hepatic phosphatidylethanolamine (PE) levels in <italic>Mboat7</italic>-HSKO mice.</title><p>Age-matched female <italic>Mboat</italic>7<sup>fl/fl</sup> or <italic>Mboat</italic>7-HSKO mice were subjected to the NIAAA model of ethanol exposure, and untargeted lipidomics was performed in the liver. The molecular species of PE were quantified via liquid chromatography–mass spectrometry (<italic>n</italic> = 6/group). Data represent the mean ± standard error of the mean (SEM) and groups not sharing a common letter superscript differ significantly (p ≤ 0.05).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-92243-fig3-figsupp7-v1.tif"/></fig><fig id="fig3s8" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 8.</label><caption><title>Hepatic phosphatidic acid (PA) levels in <italic>Mboat7</italic>-HSKO mice.</title><p>Age-matched female <italic>Mboat</italic>7<sup>fl/fl</sup> or <italic>Mboat</italic>7-HSKO mice were subjected to the NIAAA model of ethanol exposure, and untargeted lipidomics was performed in the liver. The molecular species of PA were quantified via liquid chromatography–mass spectrometry (<italic>n</italic> = 6/group). Data represent the mean ± standard error of the mean (SEM) and groups not sharing a common letter superscript differ significantly (p ≤ 0.05).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-92243-fig3-figsupp8-v1.tif"/></fig><fig id="fig3s9" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 9.</label><caption><title>Hepatic sphingomyelin (SM) levels in <italic>Mboat7</italic>-HSKO mice.</title><p>Age-matched female <italic>Mboat</italic>7<sup>fl/fl</sup> or <italic>Mboat</italic>7-HSKO mice were subjected to the NIAAA model of ethanol exposure, and untargeted lipidomics was performed in the liver. The molecular species of SM were quantified via liquid chromatography–mass spectrometry (<italic>n</italic> = 6/group). Data represent the mean ± standard error of the mean (SEM) and groups not sharing a common letter superscript differ significantly (p ≤ 0.05).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-92243-fig3-figsupp9-v1.tif"/></fig><fig id="fig3s10" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 10.</label><caption><title>Hepatic ceramide (Cer) levels in <italic>Mboat7</italic>-HSKO mice.</title><p>Age-matched female <italic>Mboat</italic>7<sup>fl/fl</sup> or <italic>Mboat</italic>-HSKO mice were subjected to the NIAAA model of ethanol exposure, and untargeted lipidomics was performed in the liver. The molecular species of ceramides were quantified via liquid chromatography–mass spectrometry (<italic>n</italic> = 6/group). Data represent the mean ± standard error of the mean (SEM) and groups not sharing a common letter superscript differ significantly (p ≤ 0.05).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-92243-fig3-figsupp10-v1.tif"/></fig><fig id="fig3s11" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 11.</label><caption><title>Hepatic ether-linked lipids levels in <italic>Mboat7</italic>-HSKO mice.</title><p>Age-matched female <italic>Mboat</italic>7<sup>fl/fl</sup> or <italic>Mboat</italic>7-HSKO mice were subjected to the NIAAA model of ethanol exposure, and untargeted lipidomics was performed in the liver. The molecular species of ether-linked lipids were quantified via liquid chromatography–mass spectrometry (<italic>n</italic> = 6/group). Data represent the mean ± standard error of the mean (SEM) and groups not sharing a common letter superscript differ significantly (p ≤ 0.05).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-92243-fig3-figsupp11-v1.tif"/></fig></fig-group><p>Given this unexpected interaction between ethanol exposure and MBOAT7 within the inositol-containing phospholipid pool, we examined the hepatic lipidome more broadly. Using untargeted lipidomics, we identified a striking remodeling of the global hepatic lipidome upon ethanol feeding in <italic>Mboat7</italic>-HSKO mice (<xref ref-type="fig" rid="fig3">Figure 3</xref>; <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplements 1</xref>–<xref ref-type="fig" rid="fig3s11">11</xref>). Unexpectedly, we observed a large increase in the levels of endosomal/lysosomal lipids including bis(monoacylglycero)phosphates (BMPs) and their outer mitochondrial membrane precursor phosphatidylglycerols (PGs) in ethanol-exposed <italic>Mboat7</italic>-HSKO mice (<xref ref-type="fig" rid="fig3">Figure 3E–G</xref>; <xref ref-type="fig" rid="fig3s3">Figure 3—figure supplements 3</xref> and <xref ref-type="fig" rid="fig3s4">4</xref>). In addition, <italic>Mboat7</italic>-HSKO mice had elevated levels of cardiolipin species, which are known to localize to mitochondria (<xref ref-type="fig" rid="fig3">Figure 3E and H</xref>; <xref ref-type="fig" rid="fig3s5">Figure 3—figure supplement 5</xref>). Under the pair- and ethanol-fed conditions studies here, <italic>Mboat7</italic>-HSKO mice also exhibited some more minor alterations in certain species of phosphatidylcholine (PC), phosphatidylethanolamine (PE), phosphatidylserine (PS), phosphatidic acid (PA), sphingomyelin (SM), ceramides (Cer), and ether-linked phospholipids (<xref ref-type="fig" rid="fig3">Figure 3E</xref>; <xref ref-type="fig" rid="fig3">Figure 3</xref>, <xref ref-type="fig" rid="fig3s2">Figure 3—figure supplements 2; 7</xref>–<xref ref-type="fig" rid="fig3s11">11</xref>). Although several recent studies examining hepatocyte-specific <italic>Mboat7</italic>-HSKO mice have found more limited effects on the global lipidome under experimental conditions designed to stimulate non-alcoholic steatohepatitis (<xref ref-type="bibr" rid="bib42">Tanaka et al., 2021</xref>; <xref ref-type="bibr" rid="bib46">Thangapandi et al., 2021</xref>; <xref ref-type="bibr" rid="bib49">Xia et al., 2021</xref>), here we show that upon ethanol exposure, hepatocyte MBOAT7 plays a major role in shaping endosomal/lysosomal lipid homeostasis.</p></sec><sec id="s2-4"><title><italic>Mboat7</italic>-HSKO mice have dysregulated lysosomal function in response to ethanol</title><p>Given the accumulation of endosomal/lysosomal lipids including BMPs seen in ethanol-fed <italic>Mboat7</italic>-HSKO mice, we hypothesized that ethanol may perturb lysosome function in a MBOAT7-driven manner to promote liver injury. It is well known that BMPs commonly accumulate in both drug-induced and genetic lysosomal storage disorders (<xref ref-type="bibr" rid="bib20">Gruenberg, 2020</xref>; <xref ref-type="bibr" rid="bib40">Showalter et al., 2020</xref>; <xref ref-type="bibr" rid="bib23">Hullin-Matsuda et al., 2014</xref>), and due to their cone-shaped structure BMPs can contribute to significant membrane asymmetry that impacts intracellular lipid sorting, apoptosis, and autophagic flux (<xref ref-type="bibr" rid="bib20">Gruenberg, 2020</xref>; <xref ref-type="bibr" rid="bib40">Showalter et al., 2020</xref>; <xref ref-type="bibr" rid="bib23">Hullin-Matsuda et al., 2014</xref>). At the same time, there is emerging evidence that chronic ethanol exposure can reduce the expression of transcription factor EB (TFEB), which is a master regulator of lysosomal biogenesis and autophagy-associated gene expression (<xref ref-type="bibr" rid="bib11">Chao et al., 2018</xref>). Given the role that lysosomal dysfunction plays in ethanol-induced liver injury (<xref ref-type="bibr" rid="bib11">Chao et al., 2018</xref>; <xref ref-type="bibr" rid="bib4">Bala and Szabo, 2018</xref>), and the unexpected accumulation of BMP lipids in <italic>Mboat7</italic>-HSKO mice, we next investigated TFEB-mediated lysosomal biogenesis and autophagy regulation in <italic>Mboat7</italic>-HSKO mice challenged with ethanol (<xref ref-type="fig" rid="fig4">Figure 4</xref>). First, <italic>Mboat7</italic>-HSKO mice showed elevated levels of key autophagy regulatory proteins LC3-I/II and p62 in the liver, particularly under ethanol-fed conditions (<xref ref-type="fig" rid="fig4">Figure 4A</xref>). Interestingly, <italic>Mboat7</italic>-HSKO mice also had increased total levels of the mammalian target of rapamycin (mTOR) (<xref ref-type="fig" rid="fig4">Figure 4A</xref>), which is a well-known master regulator of autophagic flux. The accumulation of p62 and LC3-I/II cannot distinguish between enhanced or defective autophagic flux, so we next examined potential alterations in lysosome abundance and function. Interestingly, both mRNA and protein levels of lysosomal marker proteins LAMP-1 and LAMP-2 were reduced in ethanol-fed <italic>Mboat7</italic>-HSKO mice (<xref ref-type="fig" rid="fig4">Figure 4A, D</xref>). Furthermore, compared to control mice fed ethanol, we found that ethanol <italic>Mboat7</italic>-HSKO mice had generally reduced expressions levels of TFEB target genes and proteins associated with lysosome acidification and lipid turnover including ATPase H<sup>+</sup> transporting V1 subunits A, H, and D (<italic>Atp6v1a</italic>, <italic>Atp6v1h</italic>, and <italic>Atp6v1d</italic>), α galactosidase A (<italic>Gla</italic>), chloride channel 7 α (<italic>Clcn7</italic>), and mucolipin TRP cation channel 1 (<italic>Mcoln1</italic>) (<xref ref-type="fig" rid="fig4">Figure 4A, D</xref>). Similarly, the mRNA expression, and total and nuclear protein abundance of TFEB was reduced in ethanol-fed <italic>Mboat7</italic>-HSKO mice compared to ethanol-fed <italic>Mboat7</italic><sup>flox/flox</sup> control mice (<xref ref-type="fig" rid="fig4">Figure 4A, B and D</xref>). In contrast, the expression of key autophagy related genes including <italic>Atg2b</italic>, <italic>Atg3</italic>, <italic>Atg7</italic>, <italic>Atg8</italic>, and Unc-51-like autophagy activating kinase 1 (<italic>Ulk1</italic>) were significantly elevated in ethanol-fed <italic>Mboat7</italic>-HSKO mice compared to ethanol-fed <italic>Mboat7</italic><sup>flox/flox</sup> control mice (<xref ref-type="fig" rid="fig4">Figure 4D</xref>).</p><fig-group><fig id="fig4" position="float"><label>Figure 4.</label><caption><title><italic>Mboat7</italic>-HSKO mice have dysregulated lysosome function in response to ethanol.</title><p>Age-matched female <italic>Mboat</italic>7<sup>fl/fl</sup> or <italic>Mboat</italic>7-HSKO mice were subjected to the NIAAA model of ethanol exposure. (<bold>A</bold>) Total liver lysates were subjected to western blot analysis of major autophagy marker genes LC3A/B (P62), mammalian target of rapamycin (mTOR) and lysosome biogenesis genes (TFEB, LAMP-1, LAMP-2, and ATP6V1A). (<bold>B</bold>) Nuclear fractions from mouse livers of Mboat7<italic><sup>fl/fl</sup></italic> and <italic>Mboat7</italic>-HSKO were subjected to western blot analysis of TFEB. (<bold>C</bold>) Lysosome protein degradation activity in wild-type and MBOAT7∆-Huh7 hepatoma cells treated with or without 100 mM ethanol for 48 hr was assessed by incubating cells with 10 µg/ml of lysosome indicator for 2 hr and examined by flow cytometry. <italic>n</italic> = 5 from two experiments by normalizing to wild-type group in each experiment; mean ± standard deviation (SD) (<bold>D</bold>) Expression levels of the genes encoding functions in lysosomal hydrolase and accessory, lysosomal m involved in lysosomal biogenesis in the liver of Mboat7<italic><sup>fl/fl</sup></italic> and Mboat7-HSKO <italic>mice</italic> upon ethanol feeding. mRNA expression levels were determined by qPCR (<italic>n</italic> = 6/group). Groups not sharing a common letter superscript differ significantly (p ≤ 0.05).</p><p><supplementary-material id="fig4sdata1"><label>Figure 4—source data 1.</label><caption><title>Original file for the western blot analysis in <xref ref-type="fig" rid="fig4">Figure 4A</xref> (anti-LC3-A/B).</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-92243-fig4-data1-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig4sdata2"><label>Figure 4—source data 2.</label><caption><title>Original file for the western blot analysis in <xref ref-type="fig" rid="fig4">Figure 4A</xref> (anti-p62).</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-92243-fig4-data2-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig4sdata3"><label>Figure 4—source data 3.</label><caption><title>Original file for the western blot analysis in <xref ref-type="fig" rid="fig4">Figure 4A</xref> (anti-Total mTOR and anti-LAMP-1).</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-92243-fig4-data3-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig4sdata4"><label>Figure 4—source data 4.</label><caption><title>Original file for the western blot analysis in <xref ref-type="fig" rid="fig4">Figure 4A</xref> (anti-TFEB).</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-92243-fig4-data4-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig4sdata5"><label>Figure 4—source data 5.</label><caption><title>Original file for the western blot analysis in <xref ref-type="fig" rid="fig4">Figure 4A</xref> (anti-LAMP-2 and anti-ATP6V1A).</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-92243-fig4-data5-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig4sdata6"><label>Figure 4—source data 6.</label><caption><title>Original file for the western blot analysis in <xref ref-type="fig" rid="fig4">Figure 4A</xref> (anti-β-actin).</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-92243-fig4-data6-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig4sdata7"><label>Figure 4—source data 7.</label><caption><title>PDF containing <xref ref-type="fig" rid="fig4">Figure 4A</xref> and original scans of the relevant western blot analysis (anti-MBOAT7, anti-p62, anti-total mTOR, anti-total TFEB, anti-LAMP-1, anti-LAMP-2, anti-ATP6V1A, and anti-β-actin) with highlighted bands and sample labels.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-92243-fig4-data7-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig4sdata8"><label>Figure 4—source data 8.</label><caption><title>Original file for the western blot analysis in <xref ref-type="fig" rid="fig4">Figure 4B</xref> (anti-cytosolic-TFEB).</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-92243-fig4-data8-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig4sdata9"><label>Figure 4—source data 9.</label><caption><title>Original file for the western blot analysis in <xref ref-type="fig" rid="fig4">Figure 4B</xref> (anti-nuclear TFEB).</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-92243-fig4-data9-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig4sdata10"><label>Figure 4—source data 10.</label><caption><title>Original file for the western blot analysis in <xref ref-type="fig" rid="fig4">Figure 4B</xref> (anti-LAMIN A/C).</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-92243-fig4-data10-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig4sdata11"><label>Figure 4—source data 11.</label><caption><title>Original file for the western blot analysis in <xref ref-type="fig" rid="fig4">Figure 4B</xref> (anti-GAPDH).</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-92243-fig4-data11-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig4sdata12"><label>Figure 4—source data 12.</label><caption><title>PDF containing <xref ref-type="fig" rid="fig4">Figure 4B</xref> and original scans of the relevant western blot analysis (anti-cytosolic TFEB, anti-nuclear TFEB, anti-LAMIN A/C, and anti-GAPDH) with highlighted bands and sample labels.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-92243-fig4-data12-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-92243-fig4-v1.tif"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 1.</label><caption><title>Genetic deletion of MBOAT7 in human Huh7 cells is associated with diminished lysosome biogenesis and ethanol-induced autophagy dysregulation.</title><p>WT and <italic>MBOAT7Δ</italic> Huh7 hepatoma cells were treated with and without ethanol treatment (100 mM) for 24 (<bold>A</bold>) and 48 hr (<bold>B</bold>). Total lysate were subjected to western blot analysis of LC3A/B, P62, Total mTOR, Total TFEB, LAMP-1, LAMP-2, and ATP6V1A.</p><p><supplementary-material id="fig4s1sdata1"><label>Figure 4—figure supplement 1—source data 1.</label><caption><title>Original file for the western blot analysis in <xref ref-type="fig" rid="fig4">Figure 4A, B</xref> (anti-LC3-A/B).</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-92243-fig4-figsupp1-data1-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig4s1sdata2"><label>Figure 4—figure supplement 1—source data 2.</label><caption><title>Original file for the western blot analysis in <xref ref-type="fig" rid="fig4">Figure 4A and B</xref> (anti-p62).</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-92243-fig4-figsupp1-data2-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig4s1sdata3"><label>Figure 4—figure supplement 1—source data 3.</label><caption><title>Original file for the western blot analysis in <xref ref-type="fig" rid="fig4">Figure 4A and B</xref> (anti-Total mTOR and anti-LAMP-1).</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-92243-fig4-figsupp1-data3-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig4s1sdata4"><label>Figure 4—figure supplement 1—source data 4.</label><caption><title>Original file for the western blot analysis in <xref ref-type="fig" rid="fig4">Figure 4A and B</xref> (anti-TFEB).</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-92243-fig4-figsupp1-data4-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig4s1sdata5"><label>Figure 4—figure supplement 1—source data 5.</label><caption><title>Original file for the western blot analysis in <xref ref-type="fig" rid="fig4">Figure 4A and B</xref> (anti-LAMP-2 and anti-ATP6V1A).</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-92243-fig4-figsupp1-data5-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig4s1sdata6"><label>Figure 4—figure supplement 1—source data 6.</label><caption><title>Original file for the western blot analysis in <xref ref-type="fig" rid="fig4">Figure 4A and B</xref> (anti-β-actin).</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-92243-fig4-figsupp1-data6-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig4s1sdata7"><label>Figure 4—figure supplement 1—source data 7.</label><caption><title>PDF containing <xref ref-type="fig" rid="fig4">Figure 4A and B</xref> and original scans of the relevant western blot analysis (anti-MBOAT7, anti-p62, anti-total mTOR, anti-total TFEB, anti-LAMP-1, anti-LAMP-2, anti-ATP6V1A, and anti-β-actin) with highlighted bands and sample labels.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-92243-fig4-figsupp1-data7-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-92243-fig4-figsupp1-v1.tif"/></fig><fig id="fig4s2" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 2.</label><caption><title>Working model.</title><p>MBOAT7 loss of function in either mouse or human hepatocytes is associated with decreased transcription factor EB (TFEB)-driven lysosomal biogenesis and defective autophagy secondary to lysosomal dysfunction.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-92243-fig4-figsupp2-v1.tif"/></fig></fig-group><p>We next investigated the cell autonomous effects of ethanol on wild-type human Huh7 hepatoma cells or Huh7 cells genetically lacking <italic>MBOAT7</italic> (Huh7-Δ <italic>MBOAT7</italic>). In agreement with what we found in mouse liver, <italic>MBOAT7</italic>∆-Huh7 cells had reduced levels of total TFEB and lysosomal marker proteins including LAMP1-, LAMP-2, and ATP6V1A (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1</xref>). Furthermore, <italic>MBOAT7</italic>∆-Huh7 cells had increased levels of LC3 and total mTOR, which was particularly apparent upon ethanol exposure (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1</xref>). We next assessed lysosome protein degradation activity in wild-type and MBOAT7∆-Huh7 hepatoma cells by measuring the degradation of an exogenous lysosome indicator, quantified via median Bodipy/Alexa647 fluorescence ratio. In the absence of ethanol treatment, there was no significant difference in the lysosomal activity between wild-type and MBOAT7∆-Huh7 cells. Lysosome activity was increased by 42% in wild-type cells with ethanol treatment vs. no treatment (p &lt; 0.001, <xref ref-type="fig" rid="fig4">Figure 4C</xref>), in agreement with increased mRNA levels of several lysosomal hydrolases (<xref ref-type="fig" rid="fig4">Figure 4D</xref>). However, the lysosome activity was decreased by 45% in MBOAT7∆-Huh7 vs. wild-type cells treated with ethanol (p &lt; 0.001, <xref ref-type="fig" rid="fig4">Figure 4C</xref>). Collectively, in the presence of EtOH, deletion of <italic>MBOAT7</italic> in mouse or human hepatocytes results in defective TFEB-mediated lysosomal biogenesis and lysosome activity, which would be expected to lead to impaired autophagic flux.</p></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>This manuscript builds on our initial observation that ASO-mediated knockdown of <italic>Mboat7</italic> promotes NAFLD progression, hyperinsulinemia, and insulin resistance in mice (<xref ref-type="bibr" rid="bib21">Gwag et al., 2019</xref>). Here, we have further clarified the cell autonomous roles of <italic>Mboat7</italic> in ethanol-driven liver injury by comparing metabolic phenotypes in hepatocyte-specific (<italic>Mboat7</italic>-HSKO) and myeloid-specific (<italic>Mboat7</italic>-MSKO) mice. The major findings of the current study include the following: (1) MBOAT7 product PI species (PI 38:4 and PI 38:5) are reduced in the circulation of human consuming high levels of alcohol; (2) MBOAT7 loss of function in hepatocytes, but not myeloid cells, promotes ethanol-induced liver injury in mice; (3) hepatocyte-specific deletion of <italic>Mboat7</italic> results in expected alterations in substrate LPI and product PI lipids, but unexpectedly alters lysosomal/endosome BMP lipids in an ethanol-driven manner; (4) genetic deletion in mouse or human hepatocytes results in dysregulation of lysosomal biogenesis and autophagic flux, particularly under ethanol-challenged conditions. This work provides new insights into how genetic variation in <italic>MBOAT7</italic> may impact ALD progression in humans and mice. Importantly, this work is the first to causally link MBOAT7 loss of function in hepatocytes, but not myeloid cells, to ethanol-induced liver injury via dysregulation of lysosomal biogenesis and autophagic flux. Although not all human studies agree there is a uniform association between the rs641738 SNP with ALD, our work indicates a very powerful interaction between MBOAT7 loss of function and ethanol-induced liver injury.</p><p>Here, we have identified a striking reorganization of the hepatic lipidome in <italic>Mboat7</italic>-HSKO mice when exposed to ethanol (<xref ref-type="fig" rid="fig3">Figure 3</xref>; <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplements 1</xref>–<xref ref-type="fig" rid="fig3s11">11</xref>). In previous independent studies examining lipid alterations in <italic>Mboat7</italic>-HSKO mice under experimental conditions to elicit NAFLD and fibrosis (i.e., high fat diets or methionine/choline-deficient diets), the global lipidomic alterations in the liver were much more confined to inositol-containing phospholipids and triacylglycerols (<xref ref-type="bibr" rid="bib42">Tanaka et al., 2021</xref>; <xref ref-type="bibr" rid="bib46">Thangapandi et al., 2021</xref>). It is important to note that the work of Xia and colleagues did previously report increased levels on PG lipids specifically in isolated endoplasmic reticulum (ER) membranes from <italic>Mboat7</italic>-HSKO mice, but our work confirms and extends this to show that not only PG but precursor BMPs are significantly elevated in <italic>Mboat7</italic>-HSKO mice, particularly when challenged with ethanol. It is still unclear how MBOAT7 impacts endosomal/lysosomal BMP and mitochondrial lipids such as PG and CL under ethanol-exposed conditions, but our work clearly indicates that ethanol reorganizes the global liver lipidome in a MBOAT7-dependent manner. It is most likely that the accumulation of BMP and PG lipids seen in ethanol-challenged <italic>Mboat7</italic>-HSKO mice are not directly related to the lysophospholipid acyltransferase activity of MBOAT7. Instead, it is more plausible that the accumulation of BMPs and PGs seen in <italic>Mboat7</italic>-HSKO mice is secondary to indirect reorganization of the arachidonate PI cycle or other related lipid metabolic pathways coordinated at the ER.</p><p>For instance, the arachidonate PI cycle is initiated in the ER where inositol is added to (cytidine diphosphate)CDP-diacylglycerol (18:0/20:4) by phosphatidylinositol synthase (PIS) to produce the exact same metabolic product of MBOAT7 (PI 38:4). It is likely that both PIS-generated as well as MBOAT7-generated PI 38:4 can serve as a substrate for PI kinases to form the key second messengers known as PI phosphates [PIPs including PI(18:0/20:4)-4P, PI(18:0/20:4)-4,5<sub>P2</sub>] and related lipid mediators downstream of phospholipase C in the arachidonate PI cycle IP3, DAG(18:0/20:4), PA(18:0/20:4), and CDP-DAG(18:0/20:4). It is important to note that seminal work by <xref ref-type="bibr" rid="bib2">Anderson et al., 2013</xref> found that total PIPs, PI(18:0/20:4)-4P, and PI(18:0/20:4)-4,5<sub>P2</sub> were significantly reduced in global <italic>Mboat7</italic><sup>−/−</sup> mice. In fact, more than 85% of PIP species in cultured cells have an <italic>sn</italic>-1 18:0 and <italic>sn</italic>-2 20:4 acyl chain composition (i.e., in part originate from the MBOAT7 and PIS product PI 38:4) (<xref ref-type="bibr" rid="bib12">Clark et al., 2011</xref>; <xref ref-type="bibr" rid="bib35">Rouzer et al., 2007</xref>). These reductions in PIPs seen with <italic>Mboat7</italic> deficiency (<xref ref-type="bibr" rid="bib2">Anderson et al., 2013</xref>) could have important consequences in cellular signal transduction, given that PIPs are common second messengers generated downstream of ligand activation of numerous receptor systems including hormone, growth factor, cytokine, and chemokine receptors (<xref ref-type="bibr" rid="bib48">Wymann and Schneiter, 2008</xref>; <xref ref-type="bibr" rid="bib31">Pemberton et al., 2020</xref>; <xref ref-type="bibr" rid="bib16">Fruman et al., 2017</xref>; <xref ref-type="bibr" rid="bib22">Hoxhaj and Manning, 2020</xref>). PIPs also play diverse roles in shaping protein–lipid interactions, membrane fusion events, vesicular transport, solute channel function, and cytoskeletal arrangement (<xref ref-type="bibr" rid="bib48">Wymann and Schneiter, 2008</xref>; <xref ref-type="bibr" rid="bib31">Pemberton et al., 2020</xref>; <xref ref-type="bibr" rid="bib16">Fruman et al., 2017</xref>; <xref ref-type="bibr" rid="bib22">Hoxhaj and Manning, 2020</xref>). Most relevant to this work, anionic lipids play very important roles in controlling membrane dynamics that shape nearly all steps of autophagy including initiation of autophagosome biogenesis and autophagosome–lysosome fusion (<xref ref-type="bibr" rid="bib3">Baba and Balla, 2020</xref>; <xref ref-type="bibr" rid="bib37">Schink et al., 2016</xref>). Collectively, given the fact that MBOAT7 generates the most abundant species of PI (PI 38:4), and key cellular PIPs [PI(18:0/20:4)-4P and PI(18:0/20:4)-4,5<sub>P2</sub>], there is a strong potential that the primary alterations in PI and PIP lipids could broadly alter cellular signal transduction, endosomal/lysosomal lipid sorting, membrane fusion events, vesicular transport, solute channel function, cytoskeletal arrangement, and autophagic flux.</p><p>Collectively, this work provides new cellular and molecular insights into how genetic variation in <italic>MBOAT7</italic> impacts ALD progression in humans and mice. This work is the first to causally link MBOAT7 loss of function in hepatocytes, but not myeloid cells, to ethanol-induced liver injury via dysregulation of lysosomal biogenesis and autophagic flux and broaden our understanding of the lipid metabolic mechanisms promoting ethanol-induced liver injury. This work also shows that MBOAT7-driven LPI acylation in the ER can indirectly impact both lysosomal (BMP) and mitochondrial (CL and PG) lipids which can have broad impacts on autophagy described here, as well as defective fatty acid oxidation as we originally reported in high fat diet-fed mice (<xref ref-type="bibr" rid="bib21">Gwag et al., 2019</xref>). The results of this work have broad potential implications in the management of both alcoholic- and non-alcoholic fatty liver disease, indicating that strategies that effectively restore both lysosomal and mitochondrial function may hold some therapeutic promise in humans with the common MBOAT7 rs641738 variant.</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><table-wrap id="keyresource" position="anchor"><label>Key resources table</label><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Reagent type (species) or resource</th><th align="left" valign="bottom">Designation</th><th align="left" valign="bottom">Source or reference</th><th align="left" valign="bottom">Identifiers</th><th align="left" valign="bottom">Additional information</th></tr></thead><tbody><tr><td align="left" valign="bottom">Genetic reagent (<italic>M. musculus</italic>)</td><td align="left" valign="bottom"><italic>Mboat7tm1a(KOMP)Wtsi/Mboat7tm1a(KOMP)Wtsi</italic></td><td align="left" valign="bottom">PMID:<ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/23472195/">23472195</ext-link></td><td align="left" valign="bottom">RRID: <ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:MGI:5510874">MGI:5510874</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Genetic reagent (<italic>M. musculus)</italic></td><td align="left" valign="bottom"><italic>B6N.Cg-Speer6-ps1<sup>Tg(Alb-cre)21Mgn</sup>/J</italic></td><td align="left" valign="bottom">Jackson Laboratory</td><td align="left" valign="bottom">Stock#: 018961<break/>RRID: <ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:IMSR_JAX:018961">IMSR_JAX:018961</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Genetic reagent (<italic>M. musculus</italic>)</td><td align="left" valign="bottom"><italic>B6.129P2-Lyz2<sup>tm1(cre)Ifo</sup>/J</italic></td><td align="left" valign="bottom">Jackson Laboratory</td><td align="left" valign="bottom">Stock#: 004781<break/>RRID: <ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:IMSR_JAX:004781">IMSR_JAX:004781</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Cell line (<italic>Homo sapiens</italic>)</td><td align="left" valign="bottom">HUH7 (well differentiated human hepatocellular carcinoma)</td><td align="left" valign="bottom">Japanese Collection of Research Biosources Cell Bank</td><td align="left" valign="bottom">JCRB0403</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-MBOAT7 (Rat monoclonal)</td><td align="left" valign="bottom">PMID:<ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/23097495/">23097495</ext-link></td><td align="left" valign="bottom">RRID: <ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2813851">AB_2813851</ext-link></td><td align="left" valign="bottom">WB (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-rat IgG HRP secondary antibody</td><td align="left" valign="bottom">Cell Signaling</td><td align="left" valign="bottom">Cat#: 7077<break/>RRID: <ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_10694715">AB_10694715</ext-link></td><td align="left" valign="bottom">WB (1:5000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">LC3A/B (D3U4C) XP (Rabbit monoclonal)</td><td align="left" valign="bottom">Cell Signaling</td><td align="left" valign="bottom">Cat#: 12741<break/>RRID: <ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2617131">AB_2617131</ext-link></td><td align="left" valign="bottom">WB (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">SQSTM1/p62 (Rabbit polyclonal)</td><td align="left" valign="bottom">Cell Signaling</td><td align="left" valign="bottom">Cat#: 5114<break/>RRID: <ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_10624872">AB_10624872</ext-link></td><td align="left" valign="bottom">WB (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">mTOR (7C10) (Rabbit monoclonal)</td><td align="left" valign="bottom">Cell Signaling</td><td align="left" valign="bottom">Cat#: 2983<break/>RRID: <ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2105622">AB_2105622</ext-link></td><td align="left" valign="bottom">WB (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">TFEB (D2O7D) (Rabbit monoclonal)</td><td align="left" valign="bottom">Cell Signaling</td><td align="left" valign="bottom">Cat#: 37785</td><td align="left" valign="bottom">WB (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">TFEB (Rabbit polyclonal)</td><td align="left" valign="bottom">Thermo Fisher Scientific</td><td align="left" valign="bottom">Cat#: A303-673A<break/>RRID: <ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_11204751">AB_11204751</ext-link></td><td align="left" valign="bottom">WB (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">LAMP1 (D2D11) XP Rabbit monoclonal</td><td align="left" valign="bottom">Cell Signaling</td><td align="left" valign="bottom">Cat#: 9091<break/>RRID: <ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2687579">AB_2687579</ext-link></td><td align="left" valign="bottom">WB (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">LAMP-1 (Rat monoclonal)</td><td align="left" valign="bottom">Developmental Studies Hybridoma Bank (DSHB)</td><td align="left" valign="bottom">Cat#: ID4B<break/>RRID: <ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_528127">AB_528127</ext-link></td><td align="left" valign="bottom">WB (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">LAMP-2 (Rat monoclonal)</td><td align="left" valign="bottom">Developmental Studies Hybridoma Bank (DSHB)</td><td align="left" valign="bottom">Cat#: ABL-93<break/>RRID: <ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2134767">AB_2134767</ext-link></td><td align="left" valign="bottom">WB (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">LAMP2 (D5C2P) (Rabbit monoclonal)</td><td align="left" valign="bottom">Cell Signaling</td><td align="left" valign="bottom">Cat#: 49067<break/>RRID: <ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2799349">AB_2799349</ext-link></td><td align="left" valign="bottom">WB (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">ATP6V1A (Rabbit polyclonal)</td><td align="left" valign="bottom">GeneTex</td><td align="left" valign="bottom">Cat#: GTX110815<break/>RRID: <ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_1949704">AB_1949704</ext-link></td><td align="left" valign="bottom">WB (1:1000)</td></tr><tr><td align="left" valign="bottom">antibody</td><td align="left" valign="bottom">Anti-GAPDH-HRP (Rabbit monoclonal)</td><td align="left" valign="bottom">Cell Signaling</td><td align="left" valign="bottom">Cat#: 8884<break/>RRID: <ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_11129865">AB_11129865</ext-link></td><td align="left" valign="bottom">WB (1:5000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Lamin A/C (4C11) (Mouse monoclonal)</td><td align="left" valign="bottom">Cell Signaling</td><td align="left" valign="bottom">Cat#: 4777</td><td align="left" valign="bottom">WB (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">HRP-conjugated Beta Actin (Mouse monoclonal)</td><td align="left" valign="bottom">Proteintech</td><td align="left" valign="bottom">Cat#: HRP-60008<break/>RRID: <ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2289225">AB_2289225</ext-link></td><td align="left" valign="bottom">WB (1:10,000)</td></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">Alanine Aminotransaminase (ALT) kit</td><td align="left" valign="bottom">Sekisui Diagnostics</td><td align="char" char="ndash" valign="bottom">318-30</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">Aspartate Aminotransferase (AST) kit</td><td align="left" valign="bottom">Sekisui Diagnostics</td><td align="char" char="ndash" valign="bottom">319-30</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">Liver Triglyceride</td><td align="left" valign="bottom">Wako</td><td align="char" char="ndash" valign="bottom">994-02891</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">Microsome Isolation</td><td align="left" valign="bottom">Abcam</td><td align="left" valign="bottom">ab206995</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">NE-PER Nuclear and Cytoplasmic Extraction Reagents</td><td align="left" valign="bottom">Thermo Fisher<break/>Scientific</td><td align="char" char="." valign="bottom">78833</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">Supersignal West Pico Plus substrate</td><td align="left" valign="bottom">Thermo Fisher<break/>Scientific</td><td align="char" char="." valign="bottom">34577</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Ammonium formate</td><td align="left" valign="bottom">Honeywell</td><td align="left" valign="bottom">Cat# 55674</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Methanol</td><td align="left" valign="bottom">Honeywell</td><td align="left" valign="bottom">Cat# LC230-4</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Water</td><td align="left" valign="bottom">Honeywell</td><td align="left" valign="bottom">Cat# LC365-4</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Acetonitrile</td><td align="left" valign="bottom">Honeywell</td><td align="left" valign="bottom">Cat# LC015-4</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Isopropanol</td><td align="left" valign="bottom">Fisher Scientific</td><td align="left" valign="bottom">Cat# A461-4</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Ethyl acetate</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">Cat# 650528</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Formic acid</td><td align="left" valign="bottom">Thermo Scientific</td><td align="left" valign="bottom">Cat# 28905</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">FA 18:0<sub>d35</sub></td><td align="left" valign="bottom">Cayman Chemical</td><td align="left" valign="bottom">Cat# 9003318</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">ACar 18:1<sub>d3</sub></td><td align="left" valign="bottom">Cayman Chemical</td><td align="left" valign="bottom">Cat# 26578</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">BMP 14:0_14:0</td><td align="left" valign="bottom">Avanti</td><td align="left" valign="bottom">Cat# 857131</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">PG 15:0_18:1<sub>d7</sub></td><td align="left" valign="bottom">Avanti</td><td align="left" valign="bottom">Cat# 91640</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Cer d18:1<sub>d7</sub>_15:0</td><td align="left" valign="bottom">Avanti</td><td align="left" valign="bottom">Cat# 860681P</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">PA 15:0_18:1<sub>d7</sub></td><td align="left" valign="bottom">Avanti</td><td align="left" valign="bottom">Cat# 791642</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">SPLASH LipidoMix II</td><td align="left" valign="bottom">Avanti</td><td align="left" valign="bottom">Cat# 330709</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">BMP 18:1_18:1</td><td align="left" valign="bottom">Avanti</td><td align="left" valign="bottom">Cat# 857133P</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">PG 18:1_18:1</td><td align="left" valign="bottom">Avanti</td><td align="left" valign="bottom">Cat# 840475P</td><td align="left" valign="bottom"/></tr></tbody></table></table-wrap><sec id="s4-1"><title>Human studies</title><p><italic>Healthy Control and Heavy Drinking Patient Selection</italic> – Healthy controls or heavy drinkers with an AUDIT score greater than &gt;16 were recruited from the Clinical Research Unit at the Cleveland Clinic or MetroHealth Hospital in Cleveland, Ohio based on medical history and physical examination. The study protocol was approved by the Institutional Review Board for the Protection of Human Subjects in Research at the Cleveland Clinic (IRB 17-718) and MetroHealth Hospital Cleveland (IRB 18-00911). All methods were performed in accordance with the internal review board’s guidelines and regulations, and written, informed consent was obtained from all subjects. Subject demographics are shown in <xref ref-type="supplementary-material" rid="fig1sdata1">Figure 1—source data 1</xref>.</p></sec><sec id="s4-2"><title>Mice and experimental diets</title><p>To generate conditional <italic>Mboat7</italic> knockout mice, we obtained ‘knockout first’ (Mboat7<sup>tm1a(KOMP)Wtsi</sup>) mice from Dr. Philip Hawkins (<xref ref-type="bibr" rid="bib2">Anderson et al., 2013</xref>), and crossed these mice with mice transgenically expressing FLP recombinase to remove the NEO cassette resulting in a conditional <italic>Mboat7</italic> floxed allele. The FLP transgene was then subsequently bred out of the line and resulting <italic>Mboat7</italic><sup>flox/WT</sup> mice, which were used to expand further downstream tissue-specific knockout lines. To generate congenic hepatocyte-specific (<italic>Mboat7</italic>-HSKO) and myeloid-specific (<italic>Mboat7</italic>-MSKO) <italic>Mboat7</italic> knockout mice we crossed mice harboring a post-FLP recombinase conditionally targeted <italic>Mboat7</italic> floxed allele (<xref ref-type="bibr" rid="bib2">Anderson et al., 2013</xref>; <xref ref-type="bibr" rid="bib28">Massey et al., 2023</xref>) to mice transgenically expressing Cre recombinase under the albumin promoter/enhancer (<xref ref-type="bibr" rid="bib32">Postic et al., 1999</xref>) or Cre knocked into the M lysozyme locus (<xref ref-type="bibr" rid="bib13">Clausen et al., 1999</xref>), respectively. These independent <italic>Mboat7</italic>-HSKO and <italic>Mboat7</italic>-MSKO lines were then backcrossed mice &gt;10 generations into the C57BL/6J background and subsequently subjected to ethanol exposure. Confirmation of sufficient backcrossing into the C57BL/6J background was confirmed by mouse genome SNP scanning at the Jackson Laboratory (Bar Harbor, ME). Age- and weight-matched female (8–10 weeks old) control (Mboat7<italic><sup>flox/flox</sup></italic>), hepatocyte-specific <italic>Mboat7</italic> knockout mice (Mboat7-HSKO), or myeloid-specific <italic>Mboat7</italic> knockout mice (Mboat7-MSKO) were maintained on a chow diet and randomized into pair- and ethanol-fed groups using the NIAAA model (<xref ref-type="bibr" rid="bib6">Bertola et al., 2013</xref>). Briefly, mice were initially fed with control Lieber–DeCarli diet ad libitum for 5 days to acclimatize them to liquid diet. Afterward, ethanol (EtOH)-fed groups were allowed free access to the ethanol Lieber–DeCarli diet containing 5% (vol/vol) ethanol for 10 days, and control groups were pair-fed with the isocaloric substituted maltose dextrins as control diet. At day 11, ethanol- and pair-fed mice were gavaged in the early morning with a single dose of ethanol (5 g/kg body weight) or isocaloric maltose dextrin, respectively, and euthanized 6 hr later (<xref ref-type="bibr" rid="bib6">Bertola et al., 2013</xref>). All mice were maintained in an Association for the Assessment and Accreditation of Laboratory Animal Care, International-approved animal facility, and all experimental protocols were approved by the Institutional Animal Care and Use Committee of the Cleveland Clinic (IACUC protocols # 2018-2053 and # 00002499).</p></sec><sec id="s4-3"><title>Histological analysis and imaging</title><p>Hematoxylin and eosin (H&amp;E) staining of paraffin-embedded liver sections was performed as previously described (<xref ref-type="bibr" rid="bib19">Gromovsky et al., 2017</xref>; <xref ref-type="bibr" rid="bib47">Warrier et al., 2015</xref>; <xref ref-type="bibr" rid="bib9">Brown et al., 2010</xref>; <xref ref-type="bibr" rid="bib7">Brown et al., 2008a</xref>; <xref ref-type="bibr" rid="bib8">Brown et al., 2008b</xref>). Histopathologic evaluation was scored in a blinded fashion by a board-certified pathologist with expertise in gastrointestinal/liver pathology (Daniela S. Allende – Cleveland Clinic). H&amp;E slides were scanned using a Leica Aperio AT2 Slide Scanner (Leica Microsystems, GmbH, Wetzlar, Germany) and images were processed using ImageScope (Aperio, Software Version 12.1).</p></sec><sec id="s4-4"><title>Immunoblotting</title><p>Whole tissue homogenates were made from tissues in a modified RIPA buffer as previously described (<xref ref-type="bibr" rid="bib47">Warrier et al., 2015</xref>; <xref ref-type="bibr" rid="bib21">Gwag et al., 2019</xref>; <xref ref-type="bibr" rid="bib38">Schugar et al., 2017</xref>; <xref ref-type="bibr" rid="bib26">Lord et al., 2016</xref>), microsome was isolated from the livers of control (<italic>Mboat7<sup>fl/fl</sup></italic>) or hepatocyte-specific <italic>Mboat7</italic> knockout mice (<italic>Mboat7</italic>-HSKO) using microsome isolation kit from Abcam and protein was quantified using the bicinchoninic assay (Pierce). Proteins were separated by 4–12% sodium dodecyl sulfate–polyacrylamide gel electrophoresis transferred to polyvinylidene difluoride membranes, and then proteins were detected after incubation with specific antibodies as previously described (<xref ref-type="bibr" rid="bib47">Warrier et al., 2015</xref>; <xref ref-type="bibr" rid="bib21">Gwag et al., 2019</xref>; <xref ref-type="bibr" rid="bib38">Schugar et al., 2017</xref>; <xref ref-type="bibr" rid="bib26">Lord et al., 2016</xref>) and listed in the Key resources table.</p></sec><sec id="s4-5"><title>Real-time PCR analysis of gene expression</title><p>Tissue RNA extraction and qPCR analysis were performed as previously described (<xref ref-type="bibr" rid="bib21">Gwag et al., 2019</xref>). The mRNA expression levels were calculated based on the ΔΔCT method using cyclophilin A as the housekeeping gene. qPCR was conducted using the Applied Biosystems 7500 Real-Time PCRsystem. All primer sequences can be found in <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>.</p></sec><sec id="s4-6"><title>Plasma and liver biochemistries</title><p>To determine the level of hepatic injury in mice fed HFD, plasma was used to analyze ALT levels using enzymatic assays as previously described (<xref ref-type="bibr" rid="bib21">Gwag et al., 2019</xref>). Extraction of liver lipids and quantification of total plasma and hepatic triglycerides were conducted using enzymatic assays as described previously (<xref ref-type="bibr" rid="bib21">Gwag et al., 2019</xref>; <xref ref-type="bibr" rid="bib19">Gromovsky et al., 2017</xref>).</p></sec><sec id="s4-7"><title>Liver lipid extraction</title><p>Lipids were extracted from liver samples as previously described (<xref ref-type="bibr" rid="bib24">Jain et al., 2022</xref>). Samples were kept on ice throughout the extraction. Briefly, liver was homogenized in 500 µl of 3:1:6 isopropanol:water:ethyl acetate containing internal standard in ceramic bead tubes (QIAGEN #13113-50) using the TissueLyzer II (QIAGEN #9244420). Samples were centrifuged at 16,000 × <italic>g</italic> for 10 min at 4°C and the lipid containing supernatant was transferred to a new 1.5 ml tube. Lipid extracts were dried in a SpeedVac (Thermo Savant RVT5105) and resuspended in 150 µl of methanol. Samples were kept at 4°C for no more than 1 week before analysis.</p></sec><sec id="s4-8"><title>Targeted quantification of LPI and PI lipids</title><p>Quantitation of LPI and PI species was performed as previously described (<xref ref-type="bibr" rid="bib21">Gwag et al., 2019</xref>) Briefly, LPI and PI standards (LPI 16:0, LPI 18:0, LPI 18:1, LPI 20:4, PI 38:4) and the two internal standards (LPI 17:1-d31, PI 34:1-d31) were purchased Avanti Polar Lipids. High-performance liquid chromatography (HPLC) grade water, methanol, and acetonitrile were purchased from Thermo Fisher Scientific. Standard LPI and PI species at concentrations of 0, 5, 20, 100, 500, and 2000 ng/ml were prepared in 90% methanol containing two internal standards at the concentration of 500 ng/ml. Samples were injected into the Shimadzu LCMS-8050 for generating the internal standard calibration curves. A triple quadrupole mass spectrometer (Quantiva, Thermos Fisher Scientific, Waltham, MA, USA) was used for analysis of LPI and PI species. The mass spectrometer was coupled to the outlet of an UHPLC system (Vanquish, Thermos Fisher Scientific, Waltham, MA, USA), including an auto sampler with refrigerated sample compartment and inline vacuum degasser. The HPLC eluent was directly injected into the triple quadrupole mass spectrometer and the analytes were ionized at ESI(Electrospray Ionization) negative mode. Analytes were quantified using Selected Reaction Monitoring (SRM) and the SRM transitions (<italic>m</italic>/<italic>z</italic>) were 571 → 255 for LPI 16:0, 599 → 283 for LPI 18:0, 597 → 281 for LPI 18:1, 619 → 303 for LPI 20:4, 885 → 241 for PI 38:4, 583 → 267 for internal standard LPI 17:1, and 866 → 281 for internal standard PI 34:1-d31. Xcalibur software was used to get the peak area for both the internal standards and LPI and PI species. The internal standard calibration curves were used to calculate the concentration of LPI and PI species in the samples.</p></sec><sec id="s4-9"><title>Untargeted lipidomics</title><p>Untargeted lipidomics was performed using an Agilent 1290 Infinity II liquid chromatograph equipped with a Waters Acquity BEH C18 column (1.7 μm 2.1 × 100 mm) coupled to an Agilent 6546 Q-TOF mass spectrometer. Mobile phase A was 60:40 acetonitrile:water and B was 90:9:1 isopropanol:acetonitrile:water with both phases buffered with 10 mM ammonium formate and 0.1% formic acid. The gradient was as follows: starting at 15% B to 30% B at 2.40 min, 48% at 3 min, 82% at 13.2 min, 99% at 13.8 min then held at 99% until 15.4 min before equilibrating 15%, held until 20 min. Samples were analyzed in both positive and negative ionizations in separate experiments with the following MS parameters: drying gas flowing 12 l/min at 250°C, nebulizer at 30 psi and sheath gas flowing 11 l/min at 300°C for positive mode. The sheath gas flow was 12 l/min at 375°C with a nebulizer pressure of 30 psi in negative mode. Both ionizations had the same voltage for capillary (4000 V), skimmer (75 V), fragmentor (190 V), and octupole (750 V). Reference masses (<italic>m</italic>/<italic>z</italic> = 121.05 and 922 for positive mode; 112.98 and 966.00 for negative mode) were continuously infused during sample runs for accurate mass calibration. Pooled samples were run in consecutive iterative MS/MS injections at a constant collision energy of 25 V to collect spectra for lipid library creation using Agilent LipidAnnotator and MS1 data were collected for all individual samples. Peak integration was performed using Agilent Profinder (v8.0) software and further curation and internal standard normalization were performed using in-house R scripts as described previously (<xref ref-type="bibr" rid="bib24">Jain et al., 2022</xref>). Untargeted data are reported in units of pmol lipid/g tissue. Principal component analysis and heatmaps were generated using MetaboAnalyst (<xref ref-type="bibr" rid="bib30">Pang et al., 2021</xref>). The first and second principal components are plotted on the <italic>x</italic>- and <italic>y</italic>-axis, respectively, and sample treatment group is indicated by color. For heatmap generation, data were pareto-scaled and the normalized intensity is indicated by color with relative increase in red and decrease in blue. The top 70 lipid features by analysis of variance (ANOVA) p-value are plotted on the <italic>y</italic>-axis and samples are grouped by Ward clustering on the <italic>x</italic>-axis. Sample treatments are distinguished by color.</p></sec><sec id="s4-10"><title>Targeted quantification of BMPs and PGs</title><p>Targeted BMP and PG lipid analysis was conducted on an Agilent 1290 Infinity II LC coupled to an Agilent 6495C QQQ mass spectrometer. The same column, mobile phases, and gradient were used for targeted analysis as for the untargeted. The MS parameters for both ionizations were as follows: drying gas temp flow of 12 l/min at 250°C with nebulizer at 35 psi and sheath gas flow of 11 l/min at 300°C. Capillary voltage was kept at 4000 V with nozzle voltage of 500 V and collision energy = 20 V. The iFunnel high pressure RF was at 150/90 V and low-pressure RF at 60/60 V for positive/negative ionizations, respectively. A sample type specific lipid library was created by running pooled liver extract multiple times in positive ionization using multiple reaction monitoring (MRM) to scan for a list of BMP/PG lipid precursor masses ([NH4]<sup>+</sup> adducts) with transitions for the respective fatty acid and diacylglycerol (−17 <italic>m</italic>/<italic>z</italic>) adducts (<xref ref-type="bibr" rid="bib18">Grabner et al., 2019</xref>). BMPs were identified by the characteristic free fatty acid fragment being much higher intensity than the diacylglycerol fragment, whereas the opposite was true for PG. In addition, BMP lipids eluted between 0.3 and 0.5 min earlier than the isomeric PG counterpart. These distinguishing characteristics were validated using commercial BMP 18:1_18:1 and PG 18:1_18:1 standards. A dynamic MRM method was created using the retention time data gathered from positive ionization tests but in negative mode scanning for the [M−H]<sup>−</sup> precursors and fatty acid fragments as BMP and PG are much more readily ionized in negative mode. Data were integrated in Agilent Quantitative analysis and peaks were manually adjusted and verified. Final units are in ng lipid/mg tissue.</p></sec><sec id="s4-11"><title>Lysosome protein degradation activity assay</title><p>Lysosome protein degradation activity was performed as previously described (<xref ref-type="bibr" rid="bib34">Robinet et al., 2021</xref>). Briefly, DQ-ovalbumin (D12053, Thermo Fisher Scientific) was labeled with Alexa Fluor 647 succinimidyl ester (A20006, Thermo Fisher Scientific) at room temperature for 1 hr (3:1 dye:protein mole ratio) to make lysosome protein degradation indicator. The reaction was stopped by incubating the conjugate with 1.5 M hydroxylamine (pH 8.5) for 1 hr at room temperature, and the conjugate was purified by extensive dialysis. Lysosome protein degradation indicator was validated in vitro by incubating with proteinase K and achieving significant increase of Bodipy/Alexa647 ratio (<xref ref-type="bibr" rid="bib34">Robinet et al., 2021</xref>). The double labeled ovalbumin has increased Bodipy fluorescence upon its degradation by decreasing its self-quenching, while Alexa647 is not changed upon its degradation and is used to normalize for cellular uptake. Wild-type or MBOAT7∆-Huh7 hepatoma cells treated with or without 100 mM ethanol for 48 hr were incubated with 10 µg/ml of lysosome indicator for 2 hr, and lysosome activity was analyzed by flow cytometry in ≈10,000 cells with a LSRFortessa device (BD). Flowjo software was used to export data for each cell for ratiometric analyses, and the median Bodipy/Alexa647 ratio for each independent well was used for analysis.</p></sec><sec id="s4-12"><title>Statistical analyses</title><p>Single comparisons between two groups were performed using two-tailed Student’s <italic>t</italic> tests with 95% confidence intervals. Comparisons involving multiple groups beyond binary comparison were assessed using one-way ANOVA with Tukey’s post hoc test. All data presented as mean ± standard error of the mean. Values were considered significant at p &lt; 0.05 (using superscripts), or ***p &lt; 0.001 and ****p &lt; 0.0001 in <xref ref-type="fig" rid="fig1">Figure 1</xref>. JMP 17.0 statistical discovery software (SAS Institute, Cary, NC, USA) was used for all statistical analyses.</p></sec></sec></body><back><sec sec-type="additional-information" id="s5"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn><fn fn-type="COI-statement" id="conf2"><p>Reviewing editor, <italic>eLife</italic></p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Resources, Data curation, Software, Formal analysis, Validation, Investigation, Visualization, Methodology, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con2"><p>Data curation, Formal analysis, Validation, Investigation, Visualization, Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con3"><p>Data curation, Investigation, Visualization, Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con4"><p>Data curation, Formal analysis, Investigation, Visualization, Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con5"><p>Data curation, Formal analysis, Validation, Investigation, Visualization, Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con6"><p>Data curation, Formal analysis, Validation, Investigation, Visualization, Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con7"><p>Data curation, Formal analysis, Validation, Investigation, Visualization, Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con8"><p>Data curation, Validation, Investigation, Visualization, Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con9"><p>Data curation, Formal analysis, Validation, Investigation, Visualization, Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con10"><p>Data curation, Formal analysis, Validation, Investigation, Visualization, Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con11"><p>Data curation, Formal analysis, Validation, Investigation, Visualization, Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con12"><p>Data curation, Formal analysis, Validation, Investigation, Visualization, Methodology</p></fn><fn fn-type="con" id="con13"><p>Data curation, Formal analysis, Validation, Investigation, Visualization, Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con14"><p>Data curation, Formal analysis, Validation, Investigation, Visualization, Methodology</p></fn><fn fn-type="con" id="con15"><p>Data curation, Formal analysis, Supervision, Validation, Investigation, Visualization, Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con16"><p>Data curation, Formal analysis, Validation, Investigation, Visualization, Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con17"><p>Data curation, Formal analysis, Supervision, Validation, Investigation, Visualization, Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con18"><p>Data curation, Formal analysis, Supervision, Validation, Investigation, Visualization, Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con19"><p>Data curation, Formal analysis, Supervision, Validation, Investigation, Visualization, Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con20"><p>Data curation, Formal analysis, Supervision, Validation, Investigation, Visualization, Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con21"><p>Data curation, Formal analysis, Supervision, Validation, Investigation, Visualization, Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con22"><p>Data curation, Formal analysis, Supervision, Validation, Investigation, Visualization, Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con23"><p>Data curation, Formal analysis, Supervision, Validation, Investigation, Visualization, Methodology, Writing – review and editing, helped design experiments and provided useful discussion directing collaborative aspects of the project</p></fn><fn fn-type="con" id="con24"><p>Conceptualization, Resources, Data curation, Software, Formal analysis, Supervision, Funding acquisition, Validation, Investigation, Visualization, Methodology, Writing – original draft, Project administration, Writing – review and editing</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>The study protocol was approved by the Institutional Review Board for the Protection of Human Subjects in Research at the Cleveland Clinic (IRB 17-718) and MetroHealth Hospital Cleveland (IRB 18-00911). All methods were performed in accordance with the internal review board's guidelines and regulations, and written, informed consent was obtained from all subjects.</p></fn><fn fn-type="other"><p>All mice were maintained in an Association for the Assessment and Accreditation of Laboratory Animal Care, International-approved animal facility, and all experimental protocols were approved by the Institutional Animal Care and Use Committee of the Cleveland Clinic (IACUC protocols # 2018-2053 and # 00002499).</p></fn></fn-group></sec><sec sec-type="supplementary-material" id="s6"><title>Additional files</title><supplementary-material id="supp1"><label>Supplementary file 1.</label><caption><title>Primers.</title></caption><media xlink:href="elife-92243-supp1-v1.docx" mimetype="application" mime-subtype="docx"/></supplementary-material><supplementary-material id="mdar"><label>MDAR checklist</label><media xlink:href="elife-92243-mdarchecklist1-v1.pdf" mimetype="application" mime-subtype="pdf"/></supplementary-material></sec><sec sec-type="data-availability" id="s7"><title>Data availability</title><p>All data generated or analyzed during this study are included in the manuscript and supporting files.</p></sec><ack id="ack"><title>Acknowledgements</title><p>This work was supported in part by National Institutes of Health grants P50 AA024333 (J.D., S.D., D.S.A., L.E.N., J.M.B.), R01 DK120679 (J.M.B.), RF1 NS133812 (J.M.B.), P01 HL147823 (J.M.B.), U01 AA026938 (L.E.N., J.M.B.), R01 DK130227 (J.M.B.), U01 AA026264 (L.E.N.), R01 HL128268 (J.D.S.), JDRF JDRF201309442 (J.S.), the Glenn and AFAR Junior Faculty Grant A22068 (J.S.), R01 DK133479 (J.S.); Hatch Grant WIS04000 (R.J., J.S.), K01 DK128022 (R.N.H.), UL1TR001998 (R.N.H.), and the American Heart Association-Postdoctoral Fellowships 19POST34380725 (I.R.). The authors would like to thank Dr. Philip Hawkins (Babraham Institute) for providing <italic>Mboat7</italic> knockout first mice.</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alharthi</surname><given-names>J</given-names></name><name><surname>Bayoumi</surname><given-names>A</given-names></name><name><surname>Thabet</surname><given-names>K</given-names></name><name><surname>Pan</surname><given-names>Z</given-names></name><name><surname>Gloss</surname><given-names>BS</given-names></name><name><surname>Latchoumanin</surname><given-names>O</given-names></name><name><surname>Lundberg</surname><given-names>M</given-names></name><name><surname>Twine</surname><given-names>NA</given-names></name><name><surname>McLeod</surname><given-names>D</given-names></name><name><surname>Alenizi</surname><given-names>S</given-names></name><name><surname>Adams</surname><given-names>LA</given-names></name><name><surname>Weltman</surname><given-names>M</given-names></name><name><surname>Berg</surname><given-names>T</given-names></name><name><surname>Liddle</surname><given-names>C</given-names></name><name><surname>George</surname><given-names>J</given-names></name><name><surname>Eslam</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>A metabolic associated fatty liver disease risk variant in MBOAT7 regulates toll like receptor induced outcomes</article-title><source>Nature Communications</source><volume>13</volume><elocation-id>7430</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-022-35158-9</pub-id><pub-id pub-id-type="pmid">36473860</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anderson</surname><given-names>KE</given-names></name><name><surname>Kielkowska</surname><given-names>A</given-names></name><name><surname>Durrant</surname><given-names>TN</given-names></name><name><surname>Juvin</surname><given-names>V</given-names></name><name><surname>Clark</surname><given-names>J</given-names></name><name><surname>Stephens</surname><given-names>LR</given-names></name><name><surname>Hawkins</surname><given-names>PT</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Lysophosphatidylinositol-acyltransferase-1 (LPIAT1) is required to maintain physiological levels of PtdIns and PtdInsP(2) in the mouse</article-title><source>PLOS ONE</source><volume>8</volume><elocation-id>e58425</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0058425</pub-id><pub-id pub-id-type="pmid">23472195</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baba</surname><given-names>T</given-names></name><name><surname>Balla</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Emerging roles of phosphatidylinositol 4-phosphate and phosphatidylinositol 4,5-bisphosphate as regulators of multiple steps in autophagy</article-title><source>Journal of Biochemistry</source><volume>168</volume><fpage>329</fpage><lpage>336</lpage><pub-id pub-id-type="doi">10.1093/jb/mvaa089</pub-id><pub-id pub-id-type="pmid">32745205</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bala</surname><given-names>S</given-names></name><name><surname>Szabo</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>TFEB, a master regulator of lysosome biogenesis and autophagy, is a new player in alcoholic liver disease</article-title><source>Digestive Medicine Research</source><volume>1</volume><elocation-id>16</elocation-id><pub-id pub-id-type="doi">10.21037/dmr.2018.09.03</pub-id><pub-id pub-id-type="pmid">30450489</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beaudoin</surname><given-names>JJ</given-names></name><name><surname>Liang</surname><given-names>T</given-names></name><name><surname>Tang</surname><given-names>Q</given-names></name><name><surname>Banini</surname><given-names>BA</given-names></name><name><surname>Shah</surname><given-names>VH</given-names></name><name><surname>Sanyal</surname><given-names>AJ</given-names></name><name><surname>Chalasani</surname><given-names>NP</given-names></name><name><surname>Gawrieh</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Role of candidate gene variants in modulating the risk and severity of alcoholic hepatitis</article-title><source>Alcoholism, Clinical and Experimental Research</source><volume>45</volume><fpage>709</fpage><lpage>719</lpage><pub-id pub-id-type="doi">10.1111/acer.14581</pub-id><pub-id pub-id-type="pmid">33616244</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bertola</surname><given-names>A</given-names></name><name><surname>Mathews</surname><given-names>S</given-names></name><name><surname>Ki</surname><given-names>SH</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Gao</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Mouse model of chronic and binge ethanol feeding (the NIAAA model)</article-title><source>Nature Protocols</source><volume>8</volume><fpage>627</fpage><lpage>637</lpage><pub-id pub-id-type="doi">10.1038/nprot.2013.032</pub-id><pub-id pub-id-type="pmid">23449255</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brown</surname><given-names>JM</given-names></name><name><surname>Chung</surname><given-names>S</given-names></name><name><surname>Sawyer</surname><given-names>JK</given-names></name><name><surname>Degirolamo</surname><given-names>C</given-names></name><name><surname>Alger</surname><given-names>HM</given-names></name><name><surname>Nguyen</surname><given-names>T</given-names></name><name><surname>Zhu</surname><given-names>X</given-names></name><name><surname>Duong</surname><given-names>MN</given-names></name><name><surname>Wibley</surname><given-names>AL</given-names></name><name><surname>Shah</surname><given-names>R</given-names></name><name><surname>Davis</surname><given-names>MA</given-names></name><name><surname>Kelley</surname><given-names>K</given-names></name><name><surname>Wilson</surname><given-names>MD</given-names></name><name><surname>Kent</surname><given-names>C</given-names></name><name><surname>Parks</surname><given-names>JS</given-names></name><name><surname>Rudel</surname><given-names>LL</given-names></name></person-group><year iso-8601-date="2008">2008a</year><article-title>Inhibition of stearoyl-coenzyme A desaturase 1 dissociates insulin resistance and obesity from atherosclerosis</article-title><source>Circulation</source><volume>118</volume><fpage>1467</fpage><lpage>1475</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.108.793182</pub-id><pub-id pub-id-type="pmid">18794388</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brown</surname><given-names>JM</given-names></name><name><surname>Bell</surname><given-names>TA</given-names></name><name><surname>Alger</surname><given-names>HM</given-names></name><name><surname>Sawyer</surname><given-names>JK</given-names></name><name><surname>Smith</surname><given-names>TL</given-names></name><name><surname>Kelley</surname><given-names>K</given-names></name><name><surname>Shah</surname><given-names>R</given-names></name><name><surname>Wilson</surname><given-names>MD</given-names></name><name><surname>Davis</surname><given-names>MA</given-names></name><name><surname>Lee</surname><given-names>RG</given-names></name><name><surname>Graham</surname><given-names>MJ</given-names></name><name><surname>Crooke</surname><given-names>RM</given-names></name><name><surname>Rudel</surname><given-names>LL</given-names></name></person-group><year iso-8601-date="2008">2008b</year><article-title>Targeted depletion of hepatic ACAT2-driven cholesterol esterification reveals a non-biliary route for fecal neutral sterol loss</article-title><source>The Journal of Biological Chemistry</source><volume>283</volume><fpage>10522</fpage><lpage>10534</lpage><pub-id pub-id-type="doi">10.1074/jbc.M707659200</pub-id><pub-id pub-id-type="pmid">18281279</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brown</surname><given-names>JM</given-names></name><name><surname>Betters</surname><given-names>JL</given-names></name><name><surname>Lord</surname><given-names>C</given-names></name><name><surname>Ma</surname><given-names>Y</given-names></name><name><surname>Han</surname><given-names>X</given-names></name><name><surname>Yang</surname><given-names>K</given-names></name><name><surname>Alger</surname><given-names>HM</given-names></name><name><surname>Melchior</surname><given-names>J</given-names></name><name><surname>Sawyer</surname><given-names>J</given-names></name><name><surname>Shah</surname><given-names>R</given-names></name><name><surname>Wilson</surname><given-names>MD</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Graham</surname><given-names>MJ</given-names></name><name><surname>Lee</surname><given-names>R</given-names></name><name><surname>Crooke</surname><given-names>R</given-names></name><name><surname>Shulman</surname><given-names>GI</given-names></name><name><surname>Xue</surname><given-names>B</given-names></name><name><surname>Shi</surname><given-names>H</given-names></name><name><surname>Yu</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>CGI-58 knockdown in mice causes hepatic steatosis but prevents diet-induced obesity and glucose intolerance</article-title><source>Journal of Lipid Research</source><volume>51</volume><fpage>3306</fpage><lpage>3315</lpage><pub-id pub-id-type="doi">10.1194/jlr.M010256</pub-id><pub-id pub-id-type="pmid">20802159</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buch</surname><given-names>S</given-names></name><name><surname>Stickel</surname><given-names>F</given-names></name><name><surname>Trépo</surname><given-names>E</given-names></name><name><surname>Way</surname><given-names>M</given-names></name><name><surname>Herrmann</surname><given-names>A</given-names></name><name><surname>Nischalke</surname><given-names>HD</given-names></name><name><surname>Brosch</surname><given-names>M</given-names></name><name><surname>Rosendahl</surname><given-names>J</given-names></name><name><surname>Berg</surname><given-names>T</given-names></name><name><surname>Ridinger</surname><given-names>M</given-names></name><name><surname>Rietschel</surname><given-names>M</given-names></name><name><surname>McQuillin</surname><given-names>A</given-names></name><name><surname>Frank</surname><given-names>J</given-names></name><name><surname>Kiefer</surname><given-names>F</given-names></name><name><surname>Schreiber</surname><given-names>S</given-names></name><name><surname>Lieb</surname><given-names>W</given-names></name><name><surname>Soyka</surname><given-names>M</given-names></name><name><surname>Semmo</surname><given-names>N</given-names></name><name><surname>Aigner</surname><given-names>E</given-names></name><name><surname>Datz</surname><given-names>C</given-names></name><name><surname>Schmelz</surname><given-names>R</given-names></name><name><surname>Brückner</surname><given-names>S</given-names></name><name><surname>Zeissig</surname><given-names>S</given-names></name><name><surname>Stephan</surname><given-names>AM</given-names></name><name><surname>Wodarz</surname><given-names>N</given-names></name><name><surname>Devière</surname><given-names>J</given-names></name><name><surname>Clumeck</surname><given-names>N</given-names></name><name><surname>Sarrazin</surname><given-names>C</given-names></name><name><surname>Lammert</surname><given-names>F</given-names></name><name><surname>Gustot</surname><given-names>T</given-names></name><name><surname>Deltenre</surname><given-names>P</given-names></name><name><surname>Völzke</surname><given-names>H</given-names></name><name><surname>Lerch</surname><given-names>MM</given-names></name><name><surname>Mayerle</surname><given-names>J</given-names></name><name><surname>Eyer</surname><given-names>F</given-names></name><name><surname>Schafmayer</surname><given-names>C</given-names></name><name><surname>Cichon</surname><given-names>S</given-names></name><name><surname>Nöthen</surname><given-names>MM</given-names></name><name><surname>Nothnagel</surname><given-names>M</given-names></name><name><surname>Ellinghaus</surname><given-names>D</given-names></name><name><surname>Huse</surname><given-names>K</given-names></name><name><surname>Franke</surname><given-names>A</given-names></name><name><surname>Zopf</surname><given-names>S</given-names></name><name><surname>Hellerbrand</surname><given-names>C</given-names></name><name><surname>Moreno</surname><given-names>C</given-names></name><name><surname>Franchimont</surname><given-names>D</given-names></name><name><surname>Morgan</surname><given-names>MY</given-names></name><name><surname>Hampe</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>A genome-wide association study confirms PNPLA3 and identifies TM6SF2 and MBOAT7 as risk loci for alcohol-related cirrhosis</article-title><source>Nature Genetics</source><volume>47</volume><fpage>1443</fpage><lpage>1448</lpage><pub-id pub-id-type="doi">10.1038/ng.3417</pub-id><pub-id pub-id-type="pmid">26482880</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chao</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Zhao</surname><given-names>K</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Williams</surname><given-names>JA</given-names></name><name><surname>Li</surname><given-names>T</given-names></name><name><surname>Chavan</surname><given-names>H</given-names></name><name><surname>Krishnamurthy</surname><given-names>P</given-names></name><name><surname>He</surname><given-names>XC</given-names></name><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Ballabio</surname><given-names>A</given-names></name><name><surname>Ni</surname><given-names>HM</given-names></name><name><surname>Ding</surname><given-names>WX</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Impaired tfeb-mediated lysosome biogenesis and autophagy promote chronic ethanol-induced liver injury and steatosis in mice</article-title><source>Gastroenterology</source><volume>155</volume><fpage>865</fpage><lpage>879</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2018.05.027</pub-id><pub-id pub-id-type="pmid">29782848</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clark</surname><given-names>J</given-names></name><name><surname>Anderson</surname><given-names>KE</given-names></name><name><surname>Juvin</surname><given-names>V</given-names></name><name><surname>Smith</surname><given-names>TS</given-names></name><name><surname>Karpe</surname><given-names>F</given-names></name><name><surname>Wakelam</surname><given-names>MJO</given-names></name><name><surname>Stephens</surname><given-names>LR</given-names></name><name><surname>Hawkins</surname><given-names>PT</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Quantification of PtdInsP3 molecular species in cells and tissues by mass spectrometry</article-title><source>Nature Methods</source><volume>8</volume><fpage>267</fpage><lpage>272</lpage><pub-id pub-id-type="doi">10.1038/nmeth.1564</pub-id><pub-id pub-id-type="pmid">21278744</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clausen</surname><given-names>BE</given-names></name><name><surname>Burkhardt</surname><given-names>C</given-names></name><name><surname>Reith</surname><given-names>W</given-names></name><name><surname>Renkawitz</surname><given-names>R</given-names></name><name><surname>Förster</surname><given-names>I</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>Conditional gene targeting in macrophages and granulocytes using LysMcre mice</article-title><source>Transgenic Research</source><volume>8</volume><fpage>265</fpage><lpage>277</lpage><pub-id pub-id-type="doi">10.1023/a:1008942828960</pub-id><pub-id pub-id-type="pmid">10621974</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cohen</surname><given-names>JC</given-names></name><name><surname>Horton</surname><given-names>JD</given-names></name><name><surname>Hobbs</surname><given-names>HH</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Human fatty liver disease: old questions and new insights</article-title><source>Science</source><volume>332</volume><fpage>1519</fpage><lpage>1523</lpage><pub-id pub-id-type="doi">10.1126/science.1204265</pub-id><pub-id pub-id-type="pmid">21700865</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fleming</surname><given-names>MF</given-names></name><name><surname>Barry</surname><given-names>KL</given-names></name><name><surname>MacDonald</surname><given-names>R</given-names></name></person-group><year iso-8601-date="1991">1991</year><article-title>The alcohol use disorders identification test (AUDIT) in a college sample</article-title><source>The International Journal of the Addictions</source><volume>26</volume><fpage>1173</fpage><lpage>1185</lpage><pub-id pub-id-type="doi">10.3109/10826089109062153</pub-id><pub-id pub-id-type="pmid">1743817</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fruman</surname><given-names>DA</given-names></name><name><surname>Chiu</surname><given-names>H</given-names></name><name><surname>Hopkins</surname><given-names>BD</given-names></name><name><surname>Bagrodia</surname><given-names>S</given-names></name><name><surname>Cantley</surname><given-names>LC</given-names></name><name><surname>Abraham</surname><given-names>RT</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>The pi3k pathway in human disease</article-title><source>Cell</source><volume>170</volume><fpage>605</fpage><lpage>635</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2017.07.029</pub-id><pub-id pub-id-type="pmid">28802037</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gijón</surname><given-names>MA</given-names></name><name><surname>Riekhof</surname><given-names>WR</given-names></name><name><surname>Zarini</surname><given-names>S</given-names></name><name><surname>Murphy</surname><given-names>RC</given-names></name><name><surname>Voelker</surname><given-names>DR</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Lysophospholipid acyltransferases and arachidonate recycling in human neutrophils</article-title><source>The Journal of Biological Chemistry</source><volume>283</volume><fpage>30235</fpage><lpage>30245</lpage><pub-id pub-id-type="doi">10.1074/jbc.M806194200</pub-id><pub-id pub-id-type="pmid">18772128</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grabner</surname><given-names>GF</given-names></name><name><surname>Fawzy</surname><given-names>N</given-names></name><name><surname>Pribasnig</surname><given-names>MA</given-names></name><name><surname>Trieb</surname><given-names>M</given-names></name><name><surname>Taschler</surname><given-names>U</given-names></name><name><surname>Holzer</surname><given-names>M</given-names></name><name><surname>Schweiger</surname><given-names>M</given-names></name><name><surname>Wolinski</surname><given-names>H</given-names></name><name><surname>Kolb</surname><given-names>D</given-names></name><name><surname>Horvath</surname><given-names>A</given-names></name><name><surname>Breinbauer</surname><given-names>R</given-names></name><name><surname>Rülicke</surname><given-names>T</given-names></name><name><surname>Rabl</surname><given-names>R</given-names></name><name><surname>Lass</surname><given-names>A</given-names></name><name><surname>Stadlbauer</surname><given-names>V</given-names></name><name><surname>Hutter-Paier</surname><given-names>B</given-names></name><name><surname>Stauber</surname><given-names>RE</given-names></name><name><surname>Fickert</surname><given-names>P</given-names></name><name><surname>Zechner</surname><given-names>R</given-names></name><name><surname>Marsche</surname><given-names>G</given-names></name><name><surname>Eichmann</surname><given-names>TO</given-names></name><name><surname>Zimmermann</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Metabolic disease and ABHD6 alter the circulating bis(monoacylglycerol)phosphate profile in mice and humans</article-title><source>Journal of Lipid Research</source><volume>60</volume><fpage>1020</fpage><lpage>1031</lpage><pub-id pub-id-type="doi">10.1194/jlr.M093351</pub-id><pub-id pub-id-type="pmid">30894461</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gromovsky</surname><given-names>AD</given-names></name><name><surname>Schugar</surname><given-names>RC</given-names></name><name><surname>Brown</surname><given-names>AL</given-names></name><name><surname>Helsley</surname><given-names>RN</given-names></name><name><surname>Burrows</surname><given-names>AC</given-names></name><name><surname>Ferguson</surname><given-names>D</given-names></name><name><surname>Zhang</surname><given-names>R</given-names></name><name><surname>Sansbury</surname><given-names>BE</given-names></name><name><surname>Lee</surname><given-names>RG</given-names></name><name><surname>Morton</surname><given-names>RE</given-names></name><name><surname>Allende</surname><given-names>DS</given-names></name><name><surname>Parks</surname><given-names>JS</given-names></name><name><surname>Spite</surname><given-names>M</given-names></name><name><surname>Brown</surname><given-names>JM</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Δ-5 fatty acid desaturase fads1 impacts metabolic disease by balancing proinflammatory and proresolving lipid mediators</article-title><source>Arteriosclerosis, Thrombosis, and Vascular Biology</source><volume>38</volume><fpage>218</fpage><lpage>231</lpage><pub-id pub-id-type="doi">10.1161/ATVBAHA.117.309660</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gruenberg</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Life in the lumen: the multivesicular endosome</article-title><source>Traffic</source><volume>21</volume><fpage>76</fpage><lpage>93</lpage><pub-id pub-id-type="doi">10.1111/tra.12715</pub-id><pub-id pub-id-type="pmid">31854087</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gwag</surname><given-names>T</given-names></name><name><surname>Meng</surname><given-names>Z</given-names></name><name><surname>Sui</surname><given-names>Y</given-names></name><name><surname>Helsley</surname><given-names>RN</given-names></name><name><surname>Park</surname><given-names>SH</given-names></name><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Greenberg</surname><given-names>RN</given-names></name><name><surname>Zhou</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Non-nucleoside reverse transcriptase inhibitor efavirenz activates PXR to induce hypercholesterolemia and hepatic steatosis</article-title><source>Journal of Hepatology</source><volume>70</volume><fpage>930</fpage><lpage>940</lpage><pub-id pub-id-type="doi">10.1016/j.jhep.2018.12.038</pub-id><pub-id pub-id-type="pmid">30677459</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoxhaj</surname><given-names>G</given-names></name><name><surname>Manning</surname><given-names>BD</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>The PI3K-AKT network at the interface of oncogenic signalling and cancer metabolism</article-title><source>Nature Reviews. Cancer</source><volume>20</volume><fpage>74</fpage><lpage>88</lpage><pub-id pub-id-type="doi">10.1038/s41568-019-0216-7</pub-id><pub-id pub-id-type="pmid">31686003</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hullin-Matsuda</surname><given-names>F</given-names></name><name><surname>Taguchi</surname><given-names>T</given-names></name><name><surname>Greimel</surname><given-names>P</given-names></name><name><surname>Kobayashi</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Lipid compartmentalization in the endosome system</article-title><source>Seminars in Cell &amp; Developmental Biology</source><volume>31</volume><fpage>48</fpage><lpage>56</lpage><pub-id pub-id-type="doi">10.1016/j.semcdb.2014.04.010</pub-id><pub-id pub-id-type="pmid">24747366</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jain</surname><given-names>R</given-names></name><name><surname>Wade</surname><given-names>G</given-names></name><name><surname>Ong</surname><given-names>I</given-names></name><name><surname>Chaurasia</surname><given-names>B</given-names></name><name><surname>Simcox</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Determination of tissue contributions to the circulating lipid pool in cold exposure via systematic assessment of lipid profiles</article-title><source>Journal of Lipid Research</source><volume>63</volume><elocation-id>100197</elocation-id><pub-id pub-id-type="doi">10.1016/j.jlr.2022.100197</pub-id><pub-id pub-id-type="pmid">35300982</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krawczyk</surname><given-names>M</given-names></name><name><surname>Rau</surname><given-names>M</given-names></name><name><surname>Schattenberg</surname><given-names>JM</given-names></name><name><surname>Bantel</surname><given-names>H</given-names></name><name><surname>Pathil</surname><given-names>A</given-names></name><name><surname>Demir</surname><given-names>M</given-names></name><name><surname>Kluwe</surname><given-names>J</given-names></name><name><surname>Boettler</surname><given-names>T</given-names></name><name><surname>Lammert</surname><given-names>F</given-names></name><name><surname>Geier</surname><given-names>A</given-names></name><collab>NAFLD Clinical Study Group</collab></person-group><year iso-8601-date="2017">2017</year><article-title>Combined effects of the PNPLA3 rs738409, TM6SF2 rs58542926, and MBOAT7 rs641738 variants on NAFLD severity: a multicenter biopsy-based study</article-title><source>Journal of Lipid Research</source><volume>58</volume><fpage>247</fpage><lpage>255</lpage><pub-id pub-id-type="doi">10.1194/jlr.P067454</pub-id><pub-id pub-id-type="pmid">27836992</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lord</surname><given-names>CC</given-names></name><name><surname>Ferguson</surname><given-names>D</given-names></name><name><surname>Thomas</surname><given-names>G</given-names></name><name><surname>Brown</surname><given-names>AL</given-names></name><name><surname>Schugar</surname><given-names>RC</given-names></name><name><surname>Burrows</surname><given-names>A</given-names></name><name><surname>Gromovsky</surname><given-names>AD</given-names></name><name><surname>Betters</surname><given-names>J</given-names></name><name><surname>Neumann</surname><given-names>C</given-names></name><name><surname>Sacks</surname><given-names>J</given-names></name><name><surname>Marshall</surname><given-names>S</given-names></name><name><surname>Watts</surname><given-names>R</given-names></name><name><surname>Schweiger</surname><given-names>M</given-names></name><name><surname>Lee</surname><given-names>RG</given-names></name><name><surname>Crooke</surname><given-names>RM</given-names></name><name><surname>Graham</surname><given-names>MJ</given-names></name><name><surname>Lathia</surname><given-names>JD</given-names></name><name><surname>Sakaguchi</surname><given-names>TF</given-names></name><name><surname>Lehner</surname><given-names>R</given-names></name><name><surname>Haemmerle</surname><given-names>G</given-names></name><name><surname>Zechner</surname><given-names>R</given-names></name><name><surname>Brown</surname><given-names>JM</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Regulation of Hepatic Triacylglycerol Metabolism by CGI-58 Does Not Require ATGL Co-activation</article-title><source>Cell Reports</source><volume>16</volume><fpage>939</fpage><lpage>949</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2016.06.049</pub-id><pub-id pub-id-type="pmid">27396333</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mancina</surname><given-names>RM</given-names></name><name><surname>Dongiovanni</surname><given-names>P</given-names></name><name><surname>Petta</surname><given-names>S</given-names></name><name><surname>Pingitore</surname><given-names>P</given-names></name><name><surname>Meroni</surname><given-names>M</given-names></name><name><surname>Rametta</surname><given-names>R</given-names></name><name><surname>Borén</surname><given-names>J</given-names></name><name><surname>Montalcini</surname><given-names>T</given-names></name><name><surname>Pujia</surname><given-names>A</given-names></name><name><surname>Wiklund</surname><given-names>O</given-names></name><name><surname>Hindy</surname><given-names>G</given-names></name><name><surname>Spagnuolo</surname><given-names>R</given-names></name><name><surname>Motta</surname><given-names>BM</given-names></name><name><surname>Pipitone</surname><given-names>RM</given-names></name><name><surname>Craxì</surname><given-names>A</given-names></name><name><surname>Fargion</surname><given-names>S</given-names></name><name><surname>Nobili</surname><given-names>V</given-names></name><name><surname>Käkelä</surname><given-names>P</given-names></name><name><surname>Kärjä</surname><given-names>V</given-names></name><name><surname>Männistö</surname><given-names>V</given-names></name><name><surname>Pihlajamäki</surname><given-names>J</given-names></name><name><surname>Reilly</surname><given-names>DF</given-names></name><name><surname>Castro-Perez</surname><given-names>J</given-names></name><name><surname>Kozlitina</surname><given-names>J</given-names></name><name><surname>Valenti</surname><given-names>L</given-names></name><name><surname>Romeo</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>The mboat7-tmc4 variant rs641738 increases risk of nonalcoholic fatty liver disease in individuals of european descent</article-title><source>Gastroenterology</source><volume>150</volume><fpage>1219</fpage><lpage>1230</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2016.01.032</pub-id><pub-id pub-id-type="pmid">26850495</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Massey</surname><given-names>WJ</given-names></name><name><surname>Varadharajan</surname><given-names>V</given-names></name><name><surname>Banerjee</surname><given-names>R</given-names></name><name><surname>Brown</surname><given-names>AL</given-names></name><name><surname>Horak</surname><given-names>AJ</given-names></name><name><surname>Hohe</surname><given-names>RC</given-names></name><name><surname>Jung</surname><given-names>BM</given-names></name><name><surname>Qiu</surname><given-names>Y</given-names></name><name><surname>Chan</surname><given-names>ER</given-names></name><name><surname>Pan</surname><given-names>C</given-names></name><name><surname>Zhang</surname><given-names>R</given-names></name><name><surname>Allende</surname><given-names>DS</given-names></name><name><surname>Willard</surname><given-names>B</given-names></name><name><surname>Cheng</surname><given-names>F</given-names></name><name><surname>Lusis</surname><given-names>AJ</given-names></name><name><surname>Brown</surname><given-names>JM</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>MBOAT7-driven lysophosphatidylinositol acylation in adipocytes contributes to systemic glucose homeostasis</article-title><source>Journal of Lipid Research</source><volume>64</volume><elocation-id>100349</elocation-id><pub-id pub-id-type="doi">10.1016/j.jlr.2023.100349</pub-id><pub-id pub-id-type="pmid">36806709</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meroni</surname><given-names>M</given-names></name><name><surname>Dongiovanni</surname><given-names>P</given-names></name><name><surname>Longo</surname><given-names>M</given-names></name><name><surname>Carli</surname><given-names>F</given-names></name><name><surname>Baselli</surname><given-names>G</given-names></name><name><surname>Rametta</surname><given-names>R</given-names></name><name><surname>Pelusi</surname><given-names>S</given-names></name><name><surname>Badiali</surname><given-names>S</given-names></name><name><surname>Maggioni</surname><given-names>M</given-names></name><name><surname>Gaggini</surname><given-names>M</given-names></name><name><surname>Fracanzani</surname><given-names>AL</given-names></name><name><surname>Romeo</surname><given-names>S</given-names></name><name><surname>Gatti</surname><given-names>S</given-names></name><name><surname>Davidson</surname><given-names>NO</given-names></name><name><surname>Gastaldelli</surname><given-names>A</given-names></name><name><surname>Valenti</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Mboat7 down-regulation by hyper-insulinemia induces fat accumulation in hepatocytes</article-title><source>EBioMedicine</source><volume>52</volume><elocation-id>102658</elocation-id><pub-id pub-id-type="doi">10.1016/j.ebiom.2020.102658</pub-id><pub-id pub-id-type="pmid">32058943</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pang</surname><given-names>Z</given-names></name><name><surname>Chong</surname><given-names>J</given-names></name><name><surname>Zhou</surname><given-names>G</given-names></name><name><surname>de Lima Morais</surname><given-names>DA</given-names></name><name><surname>Chang</surname><given-names>L</given-names></name><name><surname>Barrette</surname><given-names>M</given-names></name><name><surname>Gauthier</surname><given-names>C</given-names></name><name><surname>Jacques</surname><given-names>PÉ</given-names></name><name><surname>Li</surname><given-names>S</given-names></name><name><surname>Xia</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>MetaboAnalyst 5.0: narrowing the gap between raw spectra and functional insights</article-title><source>Nucleic Acids Research</source><volume>49</volume><fpage>W388</fpage><lpage>W396</lpage><pub-id pub-id-type="doi">10.1093/nar/gkab382</pub-id><pub-id pub-id-type="pmid">34019663</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pemberton</surname><given-names>JG</given-names></name><name><surname>Kim</surname><given-names>YJ</given-names></name><name><surname>Balla</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Integrated regulation of the phosphatidylinositol cycle and phosphoinositide-driven lipid transport at ER-PM contact sites</article-title><source>Traffic</source><volume>21</volume><fpage>200</fpage><lpage>219</lpage><pub-id pub-id-type="doi">10.1111/tra.12709</pub-id><pub-id pub-id-type="pmid">31650663</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Postic</surname><given-names>C</given-names></name><name><surname>Shiota</surname><given-names>M</given-names></name><name><surname>Niswender</surname><given-names>KD</given-names></name><name><surname>Jetton</surname><given-names>TL</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Moates</surname><given-names>JM</given-names></name><name><surname>Shelton</surname><given-names>KD</given-names></name><name><surname>Lindner</surname><given-names>J</given-names></name><name><surname>Cherrington</surname><given-names>AD</given-names></name><name><surname>Magnuson</surname><given-names>MA</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>Dual roles for glucokinase in glucose homeostasis as determined by liver and pancreatic beta cell-specific gene knock-outs using Cre recombinase</article-title><source>The Journal of Biological Chemistry</source><volume>274</volume><fpage>305</fpage><lpage>315</lpage><pub-id pub-id-type="doi">10.1074/jbc.274.1.305</pub-id><pub-id pub-id-type="pmid">9867845</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rinella</surname><given-names>ME</given-names></name><name><surname>Sanyal</surname><given-names>AJ</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Management of NAFLD: a stage-based approach</article-title><source>Nature Reviews. Gastroenterology &amp; Hepatology</source><volume>13</volume><fpage>196</fpage><lpage>205</lpage><pub-id pub-id-type="doi">10.1038/nrgastro.2016.3</pub-id><pub-id pub-id-type="pmid">26907882</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Robinet</surname><given-names>P</given-names></name><name><surname>Ritchey</surname><given-names>B</given-names></name><name><surname>Lorkowski</surname><given-names>SW</given-names></name><name><surname>Alzayed</surname><given-names>AM</given-names></name><name><surname>DeGeorgia</surname><given-names>S</given-names></name><name><surname>Schodowski</surname><given-names>E</given-names></name><name><surname>Traughber</surname><given-names>CA</given-names></name><name><surname>Smith</surname><given-names>JD</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Quantitative trait locus mapping identifies the Gpnmb gene as a modifier of mouse macrophage lysosome function</article-title><source>Scientific Reports</source><volume>11</volume><elocation-id>10249</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-021-89800-5</pub-id><pub-id pub-id-type="pmid">33986446</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rouzer</surname><given-names>CA</given-names></name><name><surname>Ivanova</surname><given-names>PT</given-names></name><name><surname>Byrne</surname><given-names>MO</given-names></name><name><surname>Brown</surname><given-names>HA</given-names></name><name><surname>Marnett</surname><given-names>LJ</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Lipid profiling reveals glycerophospholipid remodeling in zymosan-stimulated macrophages</article-title><source>Biochemistry</source><volume>46</volume><fpage>6026</fpage><lpage>6042</lpage><pub-id pub-id-type="doi">10.1021/bi0621617</pub-id><pub-id pub-id-type="pmid">17458939</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sabatine</surname><given-names>MS</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>PCSK9 inhibitors: clinical evidence and implementation</article-title><source>Nature Reviews. Cardiology</source><volume>16</volume><fpage>155</fpage><lpage>165</lpage><pub-id pub-id-type="doi">10.1038/s41569-018-0107-8</pub-id><pub-id pub-id-type="pmid">30420622</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schink</surname><given-names>KO</given-names></name><name><surname>Tan</surname><given-names>KW</given-names></name><name><surname>Stenmark</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Phosphoinositides in control of membrane dynamics</article-title><source>Annual Review of Cell and Developmental Biology</source><volume>32</volume><fpage>143</fpage><lpage>171</lpage><pub-id pub-id-type="doi">10.1146/annurev-cellbio-111315-125349</pub-id><pub-id pub-id-type="pmid">27576122</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schugar</surname><given-names>RC</given-names></name><name><surname>Shih</surname><given-names>DM</given-names></name><name><surname>Warrier</surname><given-names>M</given-names></name><name><surname>Helsley</surname><given-names>RN</given-names></name><name><surname>Burrows</surname><given-names>A</given-names></name><name><surname>Ferguson</surname><given-names>D</given-names></name><name><surname>Brown</surname><given-names>AL</given-names></name><name><surname>Gromovsky</surname><given-names>AD</given-names></name><name><surname>Heine</surname><given-names>M</given-names></name><name><surname>Chatterjee</surname><given-names>A</given-names></name><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Li</surname><given-names>XS</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Willard</surname><given-names>B</given-names></name><name><surname>Meng</surname><given-names>Y</given-names></name><name><surname>Kim</surname><given-names>H</given-names></name><name><surname>Che</surname><given-names>N</given-names></name><name><surname>Pan</surname><given-names>C</given-names></name><name><surname>Lee</surname><given-names>RG</given-names></name><name><surname>Crooke</surname><given-names>RM</given-names></name><name><surname>Graham</surname><given-names>MJ</given-names></name><name><surname>Morton</surname><given-names>RE</given-names></name><name><surname>Langefeld</surname><given-names>CD</given-names></name><name><surname>Das</surname><given-names>SK</given-names></name><name><surname>Rudel</surname><given-names>LL</given-names></name><name><surname>Zein</surname><given-names>N</given-names></name><name><surname>McCullough</surname><given-names>AJ</given-names></name><name><surname>Dasarathy</surname><given-names>S</given-names></name><name><surname>Tang</surname><given-names>WHW</given-names></name><name><surname>Erokwu</surname><given-names>BO</given-names></name><name><surname>Flask</surname><given-names>CA</given-names></name><name><surname>Laakso</surname><given-names>M</given-names></name><name><surname>Civelek</surname><given-names>M</given-names></name><name><surname>Naga Prasad</surname><given-names>SV</given-names></name><name><surname>Heeren</surname><given-names>J</given-names></name><name><surname>Lusis</surname><given-names>AJ</given-names></name><name><surname>Hazen</surname><given-names>SL</given-names></name><name><surname>Brown</surname><given-names>JM</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>The tmao-producing enzyme flavin-containing monooxygenase 3 regulates obesity and the beiging of white adipose tissue</article-title><source>Cell Reports</source><volume>19</volume><fpage>2451</fpage><lpage>2461</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2017.05.077</pub-id><pub-id pub-id-type="pmid">28636934</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shindou</surname><given-names>H</given-names></name><name><surname>Shimizu</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Acyl-CoA:lysophospholipid acyltransferases</article-title><source>The Journal of Biological Chemistry</source><volume>284</volume><fpage>1</fpage><lpage>5</lpage><pub-id pub-id-type="doi">10.1074/jbc.R800046200</pub-id><pub-id pub-id-type="pmid">18718904</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Showalter</surname><given-names>MR</given-names></name><name><surname>Berg</surname><given-names>AL</given-names></name><name><surname>Nagourney</surname><given-names>A</given-names></name><name><surname>Heil</surname><given-names>H</given-names></name><name><surname>Carraway</surname><given-names>KL</given-names></name><name><surname>Fiehn</surname><given-names>O</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>The emerging and diverse roles of bis(monoacylglycero) phosphate lipids in cellular physiology and disease</article-title><source>International Journal of Molecular Sciences</source><volume>21</volume><elocation-id>8067</elocation-id><pub-id pub-id-type="doi">10.3390/ijms21218067</pub-id><pub-id pub-id-type="pmid">33137979</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stickel</surname><given-names>F</given-names></name><name><surname>Buch</surname><given-names>S</given-names></name><name><surname>Nischalke</surname><given-names>HD</given-names></name><name><surname>Weiss</surname><given-names>KH</given-names></name><name><surname>Gotthardt</surname><given-names>D</given-names></name><name><surname>Fischer</surname><given-names>J</given-names></name><name><surname>Rosendahl</surname><given-names>J</given-names></name><name><surname>Marot</surname><given-names>A</given-names></name><name><surname>Elamly</surname><given-names>M</given-names></name><name><surname>Casper</surname><given-names>M</given-names></name><name><surname>Lammert</surname><given-names>F</given-names></name><name><surname>McQuillin</surname><given-names>A</given-names></name><name><surname>Zopf</surname><given-names>S</given-names></name><name><surname>Spengler</surname><given-names>U</given-names></name><name><surname>Marhenke</surname><given-names>S</given-names></name><name><surname>Kirstein</surname><given-names>MM</given-names></name><name><surname>Vogel</surname><given-names>A</given-names></name><name><surname>Eyer</surname><given-names>F</given-names></name><name><surname>von Felden</surname><given-names>J</given-names></name><name><surname>Wege</surname><given-names>H</given-names></name><name><surname>Buch</surname><given-names>T</given-names></name><name><surname>Schafmayer</surname><given-names>C</given-names></name><name><surname>Braun</surname><given-names>F</given-names></name><name><surname>Deltenre</surname><given-names>P</given-names></name><name><surname>Berg</surname><given-names>T</given-names></name><name><surname>Morgan</surname><given-names>MY</given-names></name><name><surname>Hampe</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Genetic variants in PNPLA3 and TM6SF2 predispose to the development of hepatocellular carcinoma in individuals with alcohol-related cirrhosis</article-title><source>The American Journal of Gastroenterology</source><volume>113</volume><fpage>1475</fpage><lpage>1483</lpage><pub-id pub-id-type="doi">10.1038/s41395-018-0041-8</pub-id><pub-id pub-id-type="pmid">29535416</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tanaka</surname><given-names>Y</given-names></name><name><surname>Shimanaka</surname><given-names>Y</given-names></name><name><surname>Caddeo</surname><given-names>A</given-names></name><name><surname>Kubo</surname><given-names>T</given-names></name><name><surname>Mao</surname><given-names>Y</given-names></name><name><surname>Kubota</surname><given-names>T</given-names></name><name><surname>Kubota</surname><given-names>N</given-names></name><name><surname>Yamauchi</surname><given-names>T</given-names></name><name><surname>Mancina</surname><given-names>RM</given-names></name><name><surname>Baselli</surname><given-names>G</given-names></name><name><surname>Luukkonen</surname><given-names>P</given-names></name><name><surname>Pihlajamäki</surname><given-names>J</given-names></name><name><surname>Yki-Järvinen</surname><given-names>H</given-names></name><name><surname>Valenti</surname><given-names>L</given-names></name><name><surname>Arai</surname><given-names>H</given-names></name><name><surname>Romeo</surname><given-names>S</given-names></name><name><surname>Kono</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>LPIAT1/MBOAT7 depletion increases triglyceride synthesis fueled by high phosphatidylinositol turnover</article-title><source>Gut</source><volume>70</volume><fpage>180</fpage><lpage>193</lpage><pub-id pub-id-type="doi">10.1136/gutjnl-2020-320646</pub-id><pub-id pub-id-type="pmid">32253259</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Teo</surname><given-names>K</given-names></name><name><surname>Abeysekera</surname><given-names>KWM</given-names></name><name><surname>Adams</surname><given-names>L</given-names></name><name><surname>Aigner</surname><given-names>E</given-names></name><name><surname>Anstee</surname><given-names>QM</given-names></name><name><surname>Banales</surname><given-names>JM</given-names></name><name><surname>Banerjee</surname><given-names>R</given-names></name><name><surname>Basu</surname><given-names>P</given-names></name><name><surname>Berg</surname><given-names>T</given-names></name><name><surname>Bhatnagar</surname><given-names>P</given-names></name><name><surname>Buch</surname><given-names>S</given-names></name><name><surname>Canbay</surname><given-names>A</given-names></name><name><surname>Caprio</surname><given-names>S</given-names></name><name><surname>Chatterjee</surname><given-names>A</given-names></name><name><surname>Ida Chen</surname><given-names>JD</given-names></name><name><surname>Chowdhury</surname><given-names>A</given-names></name><name><surname>Daly</surname><given-names>AK</given-names></name><name><surname>Datz</surname><given-names>C</given-names></name><name><surname>Gracia Hahn</surname><given-names>D</given-names></name><name><surname>DiStefano</surname><given-names>JK</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>rs641738C&gt;T near MBOAT7 is associated with liver fat, ALT and fibrosis in NAFLD: A meta-analysis</article-title><source>J. Hepatol</source><volume>74</volume><fpage>20</fpage><lpage>30</lpage><pub-id pub-id-type="doi">10.1016/j.jhep.2020.08.027</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thabet</surname><given-names>K</given-names></name><name><surname>Asimakopoulos</surname><given-names>A</given-names></name><name><surname>Shojaei</surname><given-names>M</given-names></name><name><surname>Romero-Gomez</surname><given-names>M</given-names></name><name><surname>Mangia</surname><given-names>A</given-names></name><name><surname>Irving</surname><given-names>WL</given-names></name><name><surname>Berg</surname><given-names>T</given-names></name><name><surname>Dore</surname><given-names>GJ</given-names></name><name><surname>Grønbæk</surname><given-names>H</given-names></name><name><surname>Sheridan</surname><given-names>D</given-names></name><name><surname>Abate</surname><given-names>ML</given-names></name><name><surname>Bugianesi</surname><given-names>E</given-names></name><name><surname>Weltman</surname><given-names>M</given-names></name><name><surname>Mollison</surname><given-names>L</given-names></name><name><surname>Cheng</surname><given-names>W</given-names></name><name><surname>Riordan</surname><given-names>S</given-names></name><name><surname>Fischer</surname><given-names>J</given-names></name><name><surname>Spengler</surname><given-names>U</given-names></name><name><surname>Nattermann</surname><given-names>J</given-names></name><name><surname>Wahid</surname><given-names>A</given-names></name><name><surname>Rojas</surname><given-names>A</given-names></name><name><surname>White</surname><given-names>R</given-names></name><name><surname>Douglas</surname><given-names>MW</given-names></name><name><surname>McLeod</surname><given-names>D</given-names></name><name><surname>Powell</surname><given-names>E</given-names></name><name><surname>Liddle</surname><given-names>C</given-names></name><name><surname>van der Poorten</surname><given-names>D</given-names></name><name><surname>George</surname><given-names>J</given-names></name><name><surname>Eslam</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>MBOAT7 rs641738 increases risk of liver inflammation and transition to fibrosis in chronic hepatitis C</article-title><source>Nature Communications</source><volume>7</volume><elocation-id>12757</elocation-id><pub-id pub-id-type="doi">10.1038/ncomms12757</pub-id><pub-id pub-id-type="pmid">27630043</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thabet</surname><given-names>K</given-names></name><name><surname>Chan</surname><given-names>HLY</given-names></name><name><surname>Petta</surname><given-names>S</given-names></name><name><surname>Mangia</surname><given-names>A</given-names></name><name><surname>Berg</surname><given-names>T</given-names></name><name><surname>Boonstra</surname><given-names>A</given-names></name><name><surname>Brouwer</surname><given-names>WP</given-names></name><name><surname>Abate</surname><given-names>ML</given-names></name><name><surname>Wong</surname><given-names>VWS</given-names></name><name><surname>Nazmy</surname><given-names>M</given-names></name><name><surname>Fischer</surname><given-names>J</given-names></name><name><surname>Liddle</surname><given-names>C</given-names></name><name><surname>George</surname><given-names>J</given-names></name><name><surname>Eslam</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>The membrane-bound O-acyltransferase domain-containing 7 variant rs641738 increases inflammation and fibrosis in chronic hepatitis B</article-title><source>Hepatology</source><volume>65</volume><fpage>1840</fpage><lpage>1850</lpage><pub-id pub-id-type="doi">10.1002/hep.29064</pub-id><pub-id pub-id-type="pmid">28109005</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thangapandi</surname><given-names>VR</given-names></name><name><surname>Knittelfelder</surname><given-names>O</given-names></name><name><surname>Brosch</surname><given-names>M</given-names></name><name><surname>Patsenker</surname><given-names>E</given-names></name><name><surname>Vvedenskaya</surname><given-names>O</given-names></name><name><surname>Buch</surname><given-names>S</given-names></name><name><surname>Hinz</surname><given-names>S</given-names></name><name><surname>Hendricks</surname><given-names>A</given-names></name><name><surname>Nati</surname><given-names>M</given-names></name><name><surname>Herrmann</surname><given-names>A</given-names></name><name><surname>Rekhade</surname><given-names>DR</given-names></name><name><surname>Berg</surname><given-names>T</given-names></name><name><surname>Matz-Soja</surname><given-names>M</given-names></name><name><surname>Huse</surname><given-names>K</given-names></name><name><surname>Klipp</surname><given-names>E</given-names></name><name><surname>Pauling</surname><given-names>JK</given-names></name><name><surname>Wodke</surname><given-names>JA</given-names></name><name><surname>Miranda Ackerman</surname><given-names>J</given-names></name><name><surname>von Bonin</surname><given-names>M</given-names></name><name><surname>Aigner</surname><given-names>E</given-names></name><name><surname>Datz</surname><given-names>C</given-names></name><name><surname>von Schönfels</surname><given-names>W</given-names></name><name><surname>Nehring</surname><given-names>S</given-names></name><name><surname>Zeissig</surname><given-names>S</given-names></name><name><surname>Röcken</surname><given-names>C</given-names></name><name><surname>Dahl</surname><given-names>A</given-names></name><name><surname>Chavakis</surname><given-names>T</given-names></name><name><surname>Stickel</surname><given-names>F</given-names></name><name><surname>Shevchenko</surname><given-names>A</given-names></name><name><surname>Schafmayer</surname><given-names>C</given-names></name><name><surname>Hampe</surname><given-names>J</given-names></name><name><surname>Subramanian</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Loss of hepatic Mboat7 leads to liver fibrosis</article-title><source>Gut</source><volume>70</volume><fpage>940</fpage><lpage>950</lpage><pub-id pub-id-type="doi">10.1136/gutjnl-2020-320853</pub-id><pub-id pub-id-type="pmid">32591434</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Warrier</surname><given-names>M</given-names></name><name><surname>Shih</surname><given-names>DM</given-names></name><name><surname>Burrows</surname><given-names>AC</given-names></name><name><surname>Ferguson</surname><given-names>D</given-names></name><name><surname>Gromovsky</surname><given-names>AD</given-names></name><name><surname>Brown</surname><given-names>AL</given-names></name><name><surname>Marshall</surname><given-names>S</given-names></name><name><surname>McDaniel</surname><given-names>A</given-names></name><name><surname>Schugar</surname><given-names>RC</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Sacks</surname><given-names>J</given-names></name><name><surname>Rong</surname><given-names>X</given-names></name><name><surname>de Vallim</surname><given-names>TA</given-names></name><name><surname>Chou</surname><given-names>J</given-names></name><name><surname>Ivanova</surname><given-names>PT</given-names></name><name><surname>Myers</surname><given-names>DS</given-names></name><name><surname>Brown</surname><given-names>HA</given-names></name><name><surname>Lee</surname><given-names>RG</given-names></name><name><surname>Crooke</surname><given-names>RM</given-names></name><name><surname>Graham</surname><given-names>MJ</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Parini</surname><given-names>P</given-names></name><name><surname>Tontonoz</surname><given-names>P</given-names></name><name><surname>Lusis</surname><given-names>AJ</given-names></name><name><surname>Hazen</surname><given-names>SL</given-names></name><name><surname>Temel</surname><given-names>RE</given-names></name><name><surname>Brown</surname><given-names>JM</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>The tmao-generating enzyme flavin monooxygenase 3 is a central regulator of cholesterol balance</article-title><source>Cell Reports</source><volume>10</volume><fpage>326</fpage><lpage>338</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2014.12.036</pub-id><pub-id pub-id-type="pmid">25600868</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wymann</surname><given-names>MP</given-names></name><name><surname>Schneiter</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Lipid signalling in disease</article-title><source>Nature Reviews. Molecular Cell Biology</source><volume>9</volume><fpage>162</fpage><lpage>176</lpage><pub-id pub-id-type="doi">10.1038/nrm2335</pub-id><pub-id pub-id-type="pmid">18216772</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xia</surname><given-names>M</given-names></name><name><surname>Chandrasekaran</surname><given-names>P</given-names></name><name><surname>Rong</surname><given-names>S</given-names></name><name><surname>Fu</surname><given-names>X</given-names></name><name><surname>Mitsche</surname><given-names>MA</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Hepatic deletion of Mboat7 (LPIAT1) causes activation of SREBP-1c and fatty liver</article-title><source>Journal of Lipid Research</source><volume>62</volume><elocation-id>100031</elocation-id><pub-id pub-id-type="doi">10.1194/jlr.RA120000856</pub-id><pub-id pub-id-type="pmid">32859645</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zarini</surname><given-names>S</given-names></name><name><surname>Hankin</surname><given-names>JA</given-names></name><name><surname>Murphy</surname><given-names>RC</given-names></name><name><surname>Gijón</surname><given-names>MA</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Lysophospholipid acyltransferases and arachidonate recycling in human neutrophils</article-title><source>Prostaglandins &amp; Other Lipid Mediators</source><volume>113–115</volume><fpage>52</fpage><lpage>61</lpage><pub-id pub-id-type="doi">10.1016/j.prostaglandins.2014.08.003</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Guo</surname><given-names>T</given-names></name><name><surname>Yang</surname><given-names>F</given-names></name><name><surname>Mao</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Liu</surname><given-names>C</given-names></name><name><surname>Sun</surname><given-names>Q</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Huang</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Single-nucleotide rs738409 polymorphisms in the PNPLA3 gene are strongly associated with alcoholic liver disease in Han Chinese males</article-title><source>Hepatology International</source><volume>12</volume><fpage>429</fpage><lpage>437</lpage><pub-id pub-id-type="doi">10.1007/s12072-018-9889-3</pub-id><pub-id pub-id-type="pmid">30132178</pub-id></element-citation></ref></ref-list></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.92243.3.sa0</article-id><title-group><article-title>eLife assessment</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Mistry</surname><given-names>Pramod K</given-names></name><role specific-use="editor">Reviewing Editor</role><aff><institution>Yale University</institution><country>United States</country></aff></contrib></contrib-group><kwd-group kwd-group-type="evidence-strength"><kwd>Convincing</kwd></kwd-group><kwd-group kwd-group-type="claim-importance"><kwd>Important</kwd></kwd-group></front-stub><body><p>Varadharajan et al. explore the mechanistic basis of MBOAT7 SNP association with steatotic liver disease and link its function in LPI acylation to altered lipidomics of endosomal/lysosomal system and impaired TFEB mediated lysosomal biogenesis. The findings are <bold>important</bold> with theoretical and practical implications in MAFLD, alcohol-induced hepatic steatosis, and lysosomal diseases. The strength of evidence is <bold>convincing</bold> using methodology in line with current state-of-the-art.</p></body></sub-article><sub-article article-type="referee-report" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.92243.3.sa1</article-id><title-group><article-title>Reviewer #2 (Public Review):</article-title></title-group><contrib-group><contrib contrib-type="author"><anonymous/><role specific-use="referee">Reviewer</role></contrib></contrib-group></front-stub><body><p>Summary:</p><p>The work by Varadharajan et. al. explored a previously known genetic variant and its pathophysiology in the development of alcohol-associated liver injury. It provides a plausible mechanism for how varying levels of MBOAT7 could impact the lipid metabolomics of the cell, leading to a deleterious phenotype in MBOAT7 knockout. The authors further characterized the impact of the lipidomic changes and raised lysosomal biogenesis and autophagic flux as mechanisms of how MBOAT7 deletion causes the progression of ALD.</p><p>Strengths:</p><p>Connecting the GWAS data on MBOAT7 variants with plausible pathophysiology greatly enhances the translational relevance of these findings. The global lipidomic profiling of ALD mice is also very informative and may lead to other discoveries related to lipid handling pathways.</p><p>Weaknesses:</p><p>The rationale of why MBOAT7 metabolites are lower in heavy drinkers than in normal individuals is not well explained. MBOAT7 loss of function drives ALD, but unclear if MBOAT7 deletion also drives preference for alcohol or if alcohol inhibits MBOAT7 function. Presuming most individuals studied here were WT and expressed an appropriate level of MBOAT7?</p><p>Also, discussion of mechanisms of MBOAT7-induced dysregulation of lysosomal biogenesis/autophagy, while very interesting, seems incomplete. It is not clear how MBOAT7 an enzyme involved in membrane phospholipid remodeling increases mTOR which leads to decreased TFEB target gene transcription. Furthermore, given the significant disturbances of global lipidomic profiling in MBOAT7 knockout, many pathways are potentially affected by this deletion. Further in vivo modeling that specifically addresses these pathways (TFEB targeting, mTOR inhibitor) would help strengthen the conclusions of this paper.</p></body></sub-article><sub-article article-type="author-comment" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.92243.3.sa2</article-id><title-group><article-title>Author response</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Varadharajan</surname><given-names>Venkateshwari</given-names></name><role specific-use="author">Author</role><aff><institution>Cleveland Clinic</institution><addr-line><named-content content-type="city">Cleveland</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Ramachandiran</surname><given-names>Iyappan</given-names></name><role specific-use="author">Author</role><aff><institution>Cleveland Clinic</institution><addr-line><named-content content-type="city">Cleveland</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Massey</surname><given-names>William</given-names></name><role specific-use="author">Author</role><aff><institution>Cleveland Clinic Lerner College of Medicine</institution><addr-line><named-content content-type="city">Cleveland</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Jain</surname><given-names>Raghav</given-names></name><role specific-use="author">Author</role><aff><institution>University of Wisconsin-Madison</institution><addr-line><named-content content-type="city">Madison</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Banerjee</surname><given-names>Rakhee</given-names></name><role specific-use="author">Author</role><aff><institution>Cleveland Clinic</institution><addr-line><named-content content-type="city">Cleveland</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Horak</surname><given-names>Anthony</given-names></name><role specific-use="author">Author</role><aff><institution>Cleveland Clinic Lerner College of Medicine</institution><addr-line><named-content content-type="city">Cleveland</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>McMullen</surname><given-names>Megan R</given-names></name><role specific-use="author">Author</role><aff><institution>Cleveland Clinic</institution><addr-line><named-content content-type="city">Cleveland</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Huang</surname><given-names>Emily C</given-names></name><role specific-use="author">Author</role><aff><institution>Cleveland Clinic Lerner College of Medicine</institution><addr-line><named-content content-type="city">Cleveland</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Bellar</surname><given-names>Annette</given-names></name><role specific-use="author">Author</role><aff><institution>Cleveland Clinic Lerner College of Medicine</institution><addr-line><named-content content-type="city">Cleveland</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Lorkowski</surname><given-names>Shuhui W</given-names></name><role specific-use="author">Author</role><aff><institution>Cleveland Clinic Lerner College of Medicine</institution><addr-line><named-content content-type="city">Cleveland</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Gulshan</surname><given-names>Kailash</given-names></name><role specific-use="author">Author</role><aff><institution>Cleveland State University</institution><addr-line><named-content content-type="city">Cleveland</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Helsley</surname><given-names>Robert N</given-names></name><role specific-use="author">Author</role><aff><institution>University of Kentucky</institution><addr-line><named-content content-type="city">Cleveland</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>James</surname><given-names>Isabella</given-names></name><role specific-use="author">Author</role><aff><institution>University of Wisconsin-Madison</institution><addr-line><named-content content-type="city">Madison</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Pathak</surname><given-names>Vai</given-names></name><role specific-use="author">Author</role><aff><institution>Cleveland Clinic</institution><addr-line><named-content content-type="city">Cleveland</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Dasarathy</surname><given-names>Jaividhya</given-names></name><role specific-use="author">Author</role><aff><institution>MetroHealth Medical Center</institution><addr-line><named-content content-type="city">Cleveland</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Welch</surname><given-names>Nicole</given-names></name><role specific-use="author">Author</role><aff><institution>Cleveland Clinic Lerner College of Medicine</institution><addr-line><named-content content-type="city">Cleveland</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Dasarathy</surname><given-names>Srinivasan</given-names></name><role specific-use="author">Author</role><aff><institution>Cleveland Clinic</institution><addr-line><named-content content-type="city">Cleveland</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Streem</surname><given-names>David</given-names></name><role specific-use="author">Author</role><aff><institution>Lutheran Hospital</institution><addr-line><named-content content-type="city">Cleveland</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Reizes</surname><given-names>Ofer</given-names></name><role specific-use="author">Author</role><aff><institution>Cleveland Clinic</institution><addr-line><named-content content-type="city">Cleveland</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Allende</surname><given-names>Daniela S</given-names></name><role specific-use="author">Author</role><aff><institution>Cleveland Clinic</institution><addr-line><named-content content-type="city">Cleveland</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Smith</surname><given-names>Jonathan D</given-names></name><role specific-use="author">Author</role><aff><institution>Cleveland Clinic</institution><addr-line><named-content content-type="city">Cleveland</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Simcox</surname><given-names>Judith</given-names></name><role specific-use="author">Author</role><aff><institution>University of Wisconsin-Madison</institution><addr-line><named-content content-type="city">Madison</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Nagy</surname><given-names>Laura E</given-names></name><role specific-use="author">Author</role><aff><institution>Cleveland Clinic Lerner College of Medicine</institution><addr-line><named-content content-type="city">Cleveland</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Brown</surname><given-names>Jonathan Mark</given-names></name><role specific-use="author">Author</role><aff><institution>Cleveland Clinic Lerner College of Medicine</institution><addr-line><named-content content-type="city">Cleveland</named-content></addr-line><country>United States</country></aff></contrib></contrib-group></front-stub><body><p>The following is the authors’ response to the original reviews.</p><disp-quote content-type="editor-comment"><p><bold>eLife assessment</bold></p><p>The delineation of MBOAT function is important with theoretical and practical implications in MAFLD, alcohol-induced hepatic steatosis, and lysosomal diseases. The strength of evidence is convincing using methodology in line with current state-of-the-art, with good support for the claims.</p><p><bold>Public Reviews:</bold></p><p><bold>Reviewer #1 (Public Review):</bold></p><p>Summary:</p><p>The authors provide mechanistic insights into how the loss of function of MBOAT7 promotes alcoholassociated liver disease. They showed that hepatocyte-specific genetic deletion of Mboat7 enhances ethanol-induced hepatic steatosis and increased ALT levels in a murine model of ethanol-induced liver disease. Through lipidomic profiling, they showed that mice with Mboat7 deletion demonstrated augmented ethanol-induced endosomal and lysosomal lipids, together with impaired transcription factor EB (TFEB)-mediated lysosomal biogenesis and accumulation of autophagosomes.</p><p>Strengths:</p><p>Alcohol-induced liver disease (ALD) and metabolic-associated steatotic liver disease (MASLD) are major global health problems, and polymorphism near the gene encoding MBOAT7 has been associated with these conditions. This paper is timely as it is important to gain insights on how loss of MBOAT function contributes to liver disease as this may eventually lead to therapeutic strategies. -The conclusions of the paper are mostly well supported by data.</p></disp-quote><p>We sincerely thank Reviewer #1 for constructive feedback on this work.</p><disp-quote content-type="editor-comment"><p>Weaknesses:</p><p>(1) In regards to circulating levels of MBOAT7 products, a comparison of heavy drinkers with ALD versus heavy drinkers without ALD would be more clinically relevant.</p></disp-quote><p>We agree this comparison would be an important comparison to make in future studies, but given the difficulties in accessing well-matched samples such as these we see this as beyond the scope of the current work.</p><disp-quote content-type="editor-comment"><p>(2) A few typos need to be addressed. For Figure 1 - figure supplement 1, should the second column heading be &quot;Heavy drinkers&quot; instead of &quot;Healthy drinkers&quot;? Also, in the same figure, it is unclear what the &quot;healthy&quot; subcategory under MELD means.</p></disp-quote><p>The typographical error was addressed in the main text and in all associated tables and figures.</p><disp-quote content-type="editor-comment"><p>(3) Some of the data in the tables need to be addressed/discussed. For instance, the white blood cell count (WBC) in Figure 1 - figure supplement 1 for &quot;healthy controls&quot; is 34, compared to 13.51 for drinkers. A WBC of 34 is not at all healthy and should be explained. The vast difference between BMI and also between racial distribution within the two cohorts should also be explained. Is it possible that some of these differences contributed to the different levels of circulating MBOAT7 products that were measured?</p></disp-quote><p>Sincere thanks for catching this error. In follow up, we found that some of our patient recruitment sites were using different units to report WBC counts (percent vs 1000/ml) and at this time we cannot retrospectively correct that difference. Therefore, we have incomplete WBC values for the cohort so elected to exclude that information to avoid confusing readers. A revised table is provided in revision reflecting these changes/ If we look at each site separately, values for WBC were in the normal range, so we do not think this is a major limitation of our studies. In regards to BMI and race: Race is not actually significant, but close. For BMI, there are 2 very low BMIs in the Heavy drinkers which bring that average down. We agree with Reviewer # 1 that race and / or BMI could impact MBOAT7, but larger cohorts are needed to detect such potential differences.</p><disp-quote content-type="editor-comment"><p>(4) The representation of the statistical difference between the bars in the results figures by using alphabets is a bit confusing. For instance, in figure 2C, does that mean all the bars labelled A are significantly different from B? The solid black bar seems to be very similar to the open red bar; please double check.</p></disp-quote><p>We apologize for this confusing presentation. Using the letter system, groups not sharing a common superscript differ statistically. Given this concern, we have gone back and reviewed all statistical comparisons and realized that there were several mistakes in the graph Figure 2C, Figure 3F and G, Figure 3-Supplementary Figure 1 F and Figure 3-Supplementary Figure 10H. The graphs themselves were not altered, but the denotation of statistical significance was updated with the correct letter superscripts.</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #2 (Public Review):</bold></p><p>Summary:</p><p>The work by Varadharajan et. al. explored a previously known genetic variant and its pathophysiology in the development of alcohol-associated liver injury. It provides a plausible mechanism for how varying levels of MBOAT7 could impact the lipid metabolomics of the cell, leading to a deleterious phenotype in MBOAT7 knockout. The authors further characterized the impact of the lipidomic changes and raised lysosomal biogenesis and autophagic flux as mechanisms of how MBOAT7 deletion causes the progression of ALD.</p><p>Strengths:</p><p>Connecting the GWAS data on MBOAT7 variants with plausible pathophysiology greatly enhances the translational relevance of these findings. The global lipidomic profiling of ALD mice is also very informative and may lead to other discoveries related to lipid handling pathways.</p></disp-quote><p>We sincerely thank Reviewer #1 for constructive feedback on this work.</p><disp-quote content-type="editor-comment"><p>Weaknesses:</p><p>The rationale of why MBOAT7 metabolites are lower in heavy drinkers than in normal individuals is not well explained. MBOAT7 loss of function drives ALD, but unclear if MBOAT7 deletion also drives preference for alcohol or if alcohol inhibits MBOAT7 function. Presuming most individuals studied here were WT and expressed an appropriate level of MBOAT7?</p></disp-quote><p>Although we were unable to genotype for the rs641738 SNP in the human subjects studied here, the original study by Buch et al. published in Nature Genetics performed cis expression quantitative trait lock (cis-eQTL) analyses to demonstrate that the minor disease-associated allele was associated with reduced MBOAT7 expression in subjects with alcohol-related cirrhosis. It is important to note that we did not see any evidence that alcohol preference was altered in either myeloid- or hepatocyte-specific Mboat7-knockout mice, given ethanol intake was similar in all genotypes. Additional studies are needed to address the possibility that MBOAT7 loss of function may promote alcohol preference, but we agree that this should be further investigated.</p><disp-quote content-type="editor-comment"><p>Also, the discussion of mechanisms of MBOAT7-induced dysregulation of lysosomal biogenesis/autophagy, while very interesting, seems incomplete. It is not clear how MBOAT7 an enzyme involved in membrane phospholipid remodeling increases mTOR which leads to decreased TFEB target gene transcription.</p></disp-quote><p>Although we agree with Reviewer #2 that mechanistic understanding by which MBOAT7 loss of function impacts mTOR activity and TFEB-driven lysosomal biogenesis is still incomplete, we do feel that the results published here will inform downstream investigation linking phosphatidylinositol remodeling to mTOR and TFEB. The MBOAT7 gene encodes an acyltransferase enzyme that specifically esterifies arachidonyl-CoA to lysophosphatidylinositol (LPI) to generate the predominant molecular species of phosphatidylinositol (PI) in cell membranes (38:4). It is well established that PI-related lipids can regulate membrane dynamics and signal transduction pathways. For instance PI-phosphates (PIPs) are dynamically shaped by PI kinases and phosphatases to play crucial roles in the regulation of a wide variety of cellular processes via specific interactions of PIP-binding proteins. Among PI phosphates, PI 3phosphate (PI3P) regulates vesicular trafficking pathways, including endocytosis, endosome-toGolgi retrograde transport, autophagy and mTOR signaling. Although additional work is needed to understand the molecular details of how MBOAT7-driven LPI acylation impacts mTOR and TFEB, it is not particularly surprising that PI lipid remodeling could broadly impact cell signaling.</p><disp-quote content-type="editor-comment"><p>Furthermore, given the significant disturbances of global lipidomic profiling in MBOAT7 knockout, many pathways are potentially affected by this deletion. Further in vivo modeling that specifically addresses these pathways (TFEB targeting, mTOR inhibitor) would help strengthen the conclusions of this paper.</p></disp-quote><p>We agree that further in vivo studies are needed that are beyond the scope of the current work.</p><disp-quote content-type="editor-comment"><p><bold>Recommendations for the authors:</bold></p><p><bold>Reviewer #2 (Recommendations For The Authors):</bold></p><p>(1) p values are rather hard to read. For example, Figure 2c, Hepatocyte-specific deletion of Mboat7 resulted in enhanced ethanol-induced increases in liver weight. However, doesn't look like there is a significant difference between the 2 EtOH groups in Figure 2C? Same comment for Figure 2e, not sure if pair-fed groups had a significant difference.</p><p>(2) Figure 2 Supp fig 1, what is the top band on the MBOAT7 WB?</p></disp-quote><p>We have addressed these statistical comparison comments as described above. Although we cannot be sure, it is likely that the top band on the MBOAT7 Western blot is a non-specific band that shows up with the antibody combination used given there is equal intensity in the Mboat7flox/flox and the MSKO mice (Mboat7flox/flox+LysM-Cre).</p></body></sub-article></article>